



(86) Date de dépôt PCT/PCT Filing Date: 2000/10/20
(87) Date publication PCT/PCT Publication Date: 2001/04/26
(45) Date de délivrance/Issue Date: 2013/02/12
(85) Entrée phase nationale/National Entry: 2002/04/19
(86) N° demande PCT/PCT Application No.: US 2000/029095
(87) N° publication PCT/PCT Publication No.: 2001/029056
(30) Priorité/Priority: 1999/10/20 (US09/421,213)

(51) Cl.Int./Int.Cl. *C12N 15/12* (2006.01),
A61K 31/7052 (2006.01), *A61K 39/00* (2006.01),
A61K 48/00 (2006.01), *C07H 21/02* (2006.01),
C07H 21/04 (2006.01), *C12N 15/09* (2006.01),
C12N 15/66 (2006.01), *C12N 5/10* (2006.01),
C12N 9/64 (2006.01), *C12P 21/06* (2006.01),
C12Q 1/34 (2006.01), *C12Q 1/68* (2006.01),
G01N 33/574 (2006.01)

(72) Inventeurs/Inventors:
O'BRIEN, TIMOTHY J., US;
TANIMOTO, HIROTOSHI, JP

(73) Propriétaire/Owner:

(54) Titre : TADG-15: UNE SERINE PROTEASE EXTRACELLULAIRE SUREXPRIMEE DANS DES CARCINOMES
(54) Title: TADG-15: AN EXTRACELLULAR SERINE PROTEASE OVEREXPRESSED IN CARCINOMAS

(57) Abrégé/Abstract:

The present invention provides DNA encoding a TADG-15 protein as well as a TADG-15 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. The present invention further provides for methods of inhibiting TADG-15 expression and/or protease activity, methods of detecting TADG-15 mRNA and/or protein and methods of screening for TADG-15 inhibitors. Additionally, the present invention provides for cell-specific targeting via TADG-15 and methods of vaccinating an individual against TADG-15. The methods described are useful in the diagnosis, treatment and prevention of cancer, particularly breast and ovarian cancer.

(73) **Propriétaires(suite)/Owners(continued):**THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, US

(74) **Agent:** BORDEN LADNER GERVAIS LLP

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 April 2001 (26.04.2001)

PCT

(10) International Publication Number
WO 01/29056 A1

- (51) International Patent Classification⁷: **C07H 21/02**, 21/04, C12Q 1/68, C12P 21/06, C12N 15/00, 15/09
- (74) Agent: **ADLER, Benjamin, A.**; McGregor & Adler, 8011 Candle Ln., Houston, TX 77071 (US).
- (21) International Application Number: PCT/US00/29095
- (81) Designated States (*national*): AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 20 October 2000 (20.10.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/421,213 20 October 1999 (20.10.1999) US
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant: **THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS** [US/US]; 2404 North University Avenue, Little Rock, AR 72207-3608 (US).
- Published:**
— *With international search report.*
- (72) Inventors: **O'BRIEN, Timothy, J.**; 2610 North Pierce, Little Rock, AR 72207 (US). **TANIMOTO, Hirotoshi**; Nakabu-cho, 1-5-53-401, Marugame, Kagawa, 763-0033 (JP).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/29056 A1

(54) Title: TADG-15: AN EXTRACELLULAR SERINE PROTEASE OVEREXPRESSED IN CARCINOMAS

(57) Abstract: The present invention provides DNA encoding a TADG-15 protein as well as a TADG-15 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. The present invention further provides for methods of inhibiting TADG-15 expression and/or protease activity, methods of detecting TADG-15 mRNA and/or protein and methods of screening for TADG-15 inhibitors. Additionally, the present invention provides for cell-specific targeting via TADG-15 and methods of vaccinating an individual against TADG-15. The methods described are useful in the diagnosis, treatment and prevention of cancer, particularly breast and ovarian cancer.

5 **TADG-15: AN EXTRACELLULAR SERINE PROTEASE**
 OVEREXPRESSED IN CARCINOMAS

10 **BACKGROUND OF THE INVENTION**

15

Field of the Invention

 The present invention relates generally to the fields of
cellular biology and the diagnosis of neoplastic disease. More
20 specifically, the present invention relates to an extracellular
serine protease, termed tumor antigen-derived gene 15 (TADG-
15), which is overexpressed in carcinomas.

Description of the Related Art

25 Extracellular proteases have been directly associated
with tumor growth, shedding of tumor cells and invasion of target
organs. Individual classes of proteases are involved in, but not
limited to, (a) digestion of stroma surrounding the initial tumor
area, (b) digestion of the cellular adhesion molecules to allow

dissociation of tumor cells; and (c) invasion of the basement membrane for metastatic growth and activation of both tumor growth factors and angiogenic factors.

In the process of cancer progression and invasion, proteases mediate specific proteolysis and contribute to the removal of extracellular matrix components surrounding tumor cells, the digestion of intercellular adhesion molecules to allow dissociation of malignant cells and the activation of many growth and angiogenic factors.¹⁻³ Depending on the nature of their catalytic domain, proteases are classified into four families: serine proteases, metalloproteases, aspartic proteases and cysteine proteases.³ Among these proteases, the metalloproteases have been well studied in relation to tumor growth and progression, and they are known to be capable of degrading the extracellular matrix, thereby enhancing the invasive potential of malignant cells.^{1,4,5} For serine proteases, previous studies have demonstrated an increased production of plasminogen activator in tumor cells and a positive correlation between plasminogen activator activity and aggressiveness of cancer.^{6,7} Prostate specific antigen (a serine protease) has also been widely used as an indicator of abnormal prostate growth.⁸ More recently, several other serine proteases have been reported, viz. hepsin and the stratum corneum chymotryptic enzyme (SCCE), which are overexpressed in ovarian cancer and which may contribute to malignant progression by increasing the extracellular lytic activity of these tumor cells.⁹

The prior art is deficient in the lack of effective means of screening to identify proteases overexpressed in carcinoma.

The present invention fulfills this longstanding need and desire in the art.

5

SUMMARY OF THE INVENTION

The present invention discloses a screening program to identify proteases overexpressed in carcinoma by examining PCR products amplified using differential display in early stage tumors and metastatic tumors compared to that of normal tissues. The approach herein to identify candidate genes overexpressed in tumor cells has been to utilize the well conserved domains surrounding the triad of amino acids (His-Asp-Ser) prototypical of the catalytic domain of serine proteases. Herein, evidence is presented for a unique form of serine protease not previously described in the literature which is highly expressed in ovarian carcinomas. Through the screening approach using differential PCR amplification of normal, low malignant potential and overt carcinomas, a PCR product present only in carcinoma was subcloned and sequenced, and was found to have a catalytic domain which was consistent with the serine protease family. Reported herein is the complete cloning and sequencing of this transcript and evidence for its expression in ovarian tumor cells.

25

In one embodiment of the present invention, there is provided a DNA encoding a tumor antigen-derived gene (TADG-15) protein, selected from the following: (a) an isolated DNA which encodes a TADG-15 protein; (b) an isolated DNA which hybridizes under high stringency conditions to the isolated DNA

of (a) above and which encodes a TADG-15 protein; and (c) an isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-15 protein. The embodiment
5 further includes a vector comprising the TADG-15 DNA and regulatory elements necessary for expression of the DNA in a cell. Additionally embodied is a vector in which the TADG-15 DNA is positioned in reverse orientation relative to the regulatory elements such that TADG-15 antisense mRNA is produced.

10 In another embodiment of the present invention, there is provided an isolated and purified TADG-15 protein coded for by DNA selected from the following: (a) an isolated DNA which encodes a TADG-15 protein; (b) an isolated DNA which hybridizes under high stringency conditions to isolated DNA of
15 (a) above and which encodes a TADG-15 protein; and (c) an isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-15 protein.

In yet another embodiment of the present invention,
20 there is provided a method for detecting TADG-15 mRNA in a sample, comprising the steps of: (a) contacting a sample with a probe which is specific for TADG-15; and (b) detecting binding of the probe to TADG-15 mRNA in the sample. In still yet another embodiment of the present invention, there is provided a kit for
25 detecting TADG-15 mRNA, comprising: an oligonucleotide probe specific for TADG-15. A label for detection is further embodied in the kit.

The present invention additionally embodies a method of detecting TADG-15 protein in a sample, comprising the steps

of: (a) contacting a sample with an antibody which is specific for TADG-15 or a fragment thereof; and (b) detecting binding of the antibody to TADG-15 protein in the sample. Similarly, the present invention also embodies a kit for detecting TADG-15
5 protein, comprising: an antibody specific for TADG-15 protein or a fragment thereof. Means for detection of the antibody is further embodied in the kit.

In another embodiment, the present invention provides an antibody specific for the TADG-15 protein or a
10 fragment thereof.

In yet another embodiment, the present invention provides a method of screening for compounds that inhibit TADG-15, comprising the steps of: (a) contacting a sample comprising TADG-15 protein with a compound; and (b) assaying
15 for TADG-15 protease activity. Typically, a decrease in the TADG-15 protease activity in the presence of the compound relative to TADG-15 protease activity in the absence of the compound is indicative of a compound that inhibits TADG-15.

In still yet another embodiment of the present invention, there is provided a method of inhibiting expression of TADG-15 in a cell, comprising the step of: (a) introducing a vector into a cell, whereupon expression of the vector produces TADG-15 antisense mRNA in the cell which hybridizes to endogenous TADG-15 mRNA, thereby inhibiting expression of
20 TADG-15 in the cell.

Further embodied by the present invention, there is provided a method of inhibiting a TADG-15 protein in a cell, comprising the step of: (a) introducing an antibody specific for a TADG-15 protein or a fragment thereof into a cell, whereupon

binding of the antibody to the TADG-15 protein inhibits the TADG-15 protein.

In an embodiment of the present invention, there is provided a method of targeted therapy to an individual, comprising the step of: (a) administering a compound containing a targeting moiety and a therapeutic moiety to an individual, wherein the targeting moiety is specific for TADG-15.

In an embodiment of the present invention, there is provided a method of diagnosing cancer in an individual, comprising the steps of: (a) obtaining a biological sample from an individual; and (b) detecting TADG-15 in the sample, wherein the presence of TADG-15 in the sample is indicative of the presence of carcinoma in the individual and the absence of TADG-15 in the sample is indicative of the absence of carcinoma in the individual.

In another embodiment of the present invention, there is provided a method of vaccinating an individual against TADG-15, comprising the steps of: (a) inoculating an individual with a TADG-15 protein or fragment thereof that lacks TADG-15 protease activity, wherein the inoculation with the TADG-15 protein or fragment thereof elicits an immune response in the individual, thereby vaccinating the individual against TADG-15.

In an embodiment of the present invention, there is provided a method of producing immune-activated cells directed toward TADG-15, comprising the steps of: exposing dendritic cells to a TADG-15 protein or fragment thereof that lacks TADG-15 protease activity, wherein the exposure to said TADG-15 protein or fragment thereof activates the dendritic cells, thereby producing immune-activated cells directed toward TADG-15.

In another embodiment of the present invention, there is provided an immunogenic composition, comprising an immunogenic fragment of a TADG-15 protein and an appropriate adjuvant.

5 Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention given for the purpose of disclosure.

10

BRIEF DESCRIPTION OF THE DRAWINGS

15 So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the
20 appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.

25 **Figure 1** shows a comparison of the serine protease catalytic domain of TADG-15 with Hepsin (Heps, SEQ ID No. 3), SCCE (SEQ ID No. 4), Trypsin (Try, SEQ ID No. 5), Chymotrypsin (Chymb, SEQ ID No. 6), Factor 7 (Fac7, SEQ ID No. 7) and Tissue plasminogen activator (Tpa, SEQ ID No. 8). The asterisks indicate conserved amino acids of catalytic triad.

Figure 2 shows the nucleotide sequence of the TADG-15 cDNA and the derived amino acid sequence of the TADG-15 protein. The putative start codon is located at nucleotides 23-25. The potential transmembrane sequence is underlined. Possible N-linked glycosylation sites are indicated by a broken line. The asterisks indicate conserved cysteine residues of CUB domain. The SDE-motifs of the LDL receptor ligand binding repeat-like domain are boxed. The arrow shows the arginine-valine bond cleaved upon activation. The conserved amino acids of the catalytic triad; histidine, aspartic acid and serine residues are circled.

Figure 3 shows the amino acid sequence of the TADG-15 protease, including functional sites and domains.

Figure 4 shows a diagram of the TADG-15 protein. 1; cytoplasmic domain, (aa #1-54), 2; transmembrane domain (aa #55-57), 3; extracellular domain (aa #78-213), 4-5; CUB repeat (aa #214-447), 6-9; LDL receptor ligand binding repeat (class A motif) like domain (aa #453-602), 10; serine protease (aa #615-855).

Figure 5 shows Northern blot analysis of TADG-15 mRNA expression in normal ovary, ovarian carcinomas, carcinoma cell lines, normal fetal tissues and normal adult tissues. A single intense transcript of the TADG-15 was observed in every sub-type of carcinoma and the two ovarian carcinoma cell lines, SW626 and CAOV3, whereas no visible band was detected in normal ovary or the two breast cancer cell lines. In normal fetal tissues, fetal kidney showed increased transcript and faint expression was detected in fetal lung. In normal adult

tissues, the TADG-15 was detected in colon with low expression in small intestine and prostate.

Figure 6A shows quantitative PCR analysis of TADG-15 expression. Expression levels of TADG-15 relative to β -tubulin are significantly elevated in all LMP tumors and carcinomas compared to that of normal ovaries. m; mucinous, s; serous. **Figure 6B** shows the ratio of TADG-15 expression to expression of β -tubulin in normal ovary, LMP tumor and ovarian carcinoma. TADG-15 mRNA expression levels were significantly elevated in both LMP tumor (*; $p < 0.001$) and carcinoma (**; $p < 0.0001$) compared to that in normal ovary. All 10 samples of normal ovary showed a low level of TADG-15 expression.

Figure 7 shows the TADG-15 expression in tumor cell lines derived from both ovarian and breast carcinoma tissues.

Figure 8 shows the overexpression of TADG-15 in other tumor tissues.

Figure 9 shows SW626 and CAOV3 cell lysates that were separated by SDS-PAGE and immunoblotted. Lanes 1 and 2 were probed with rabbit pre-immune serum as a negative control. Lanes 3 and 4 were probed with polyclonal rabbit antibody generated to a carboxy terminal peptide from TADG-15 protein sequence.

Figure 10 shows that immunohistochemical staining of normal ovarian epithelium (**Figure 10A**) with a polyclonal antibody to a TADG-15 protease peptide shows no staining of the stroma or epithelium. However, antibody staining of carcinomas confirms the presence of TADG-15 expression in the cytoplasm of a serous low malignant potential tumor (**Figure 10B**); a mucinous low malignant potential tumor (**Figure 10C**); a serous

carcinoma (**Figure 10D**); and its presence in both the cytoplasm and cell surface of an endometrioid carcinoma (**Figure 10E**).

Figure 11 shows an alignment of the human TADG15 protein sequence with that of mouse epithin which demonstrates
5 that the proteins are 84% similar and 81% identical over 843 amino acids. Residues that are identical between the two proteins are indicated by a "-", while the "*" symbol represents the TADG15 translation termination. The most significant difference
10 between these two proteins lies in the carboxy-termini, which for epithin, includes 47 amino acids that are not present in TADG15.

Figure 12 shows a nucleotide sequence comparison between TADG-15 and human SNC-19 (GeneBank Accession No. #U20428).

15

DETAILED DESCRIPTION OF THE INVENTION

Proteases have been implicated in the extracellular modulation required for tumor growth and invasion. In an effort
20 to categorize those proteases contributing to ovarian carcinoma progression, redundant primers directed towards conserved amino acid domains surrounding the catalytic triad of His, Asp and Ser were utilized to amplify serine proteases differentially expressed in carcinomas. Using this method, a serine protease
25 named TADG-15 (tumor antigen-derived gene 15) has been identified that is overexpressed in ovarian tumors. TADG-15 appears to be a transmembrane multidomain serine protease. TADG-15 is highly overexpressed in ovarian tumors based on PCR, Northern blot and immunolocalization.

The TADG-15 cDNA is 3147 base pairs long (SEQ ID No. 1) encoding for a 855 amino acid protein (SEQ ID No. 2). The availability of the TADG-15 gene provides numerous utilities. For example, the TADG-15 gene can be used as a diagnostic or
5 therapeutic target in ovarian and other carcinomas, including breast, prostate, lung and colon.

The present invention is directed to DNA encoding a tumor antigen-derived gene (TADG-15) protein, selected from the following: (a) an isolated DNA which encodes a TADG-15 protein;
10 (b) an isolated DNA which hybridizes under high stringency conditions to the isolated DNA of (a) above and which encodes a TADG-15 protein; and (c) an isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-15
15 protein. It is preferred that the DNA has the sequence shown in SEQ ID No. 1 and the TADG-15 protein has the amino acid sequence shown in SEQ ID No. 2.

The present invention is directed toward a vector comprising the TADG-15 DNA and regulatory elements necessary
20 for expression of the DNA in a cell, or a vector in which the TADG-15 DNA is positioned in reverse orientation relative to the regulatory elements such that TADG-15 antisense mRNA is produced. Generally, the DNA encodes a TADG-15 protein having the amino acid sequence shown in SEQ ID No. 2. The invention is
25 also directed toward host cells transfected with either of the above-described vector(s). Representative host cells are bacterial cells, mammalian cells, plant cells and insect cells. Preferably, the bacterial cell is *E. coli*.

The present invention is directed toward an isolated and purified TADG-15 protein coded for by DNA selected from the following: (a) an isolated DNA which encodes a TADG-15 protein; (b) an isolated DNA which hybridizes under high
5 stringency conditions to isolated DNA of (a) above and which encodes a TADG-15 protein; and (c) an isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-15 protein. Preferably, the protein has the amino acid
10 sequence shown in SEQ ID No. 2.

The present invention is directed toward a method for detecting TADG-15 mRNA in a sample, comprising the steps of: (a) contacting a sample with a probe which is specific for TADG-15; and (b) detecting binding of the probe to TADG-15 mRNA in
15 the sample. The present invention is also directed toward a method of detecting TADG-15 protein in a sample, comprising the steps of: (a) contacting a sample with an antibody which is specific for TADG-15 or a fragment thereof; and (b) detecting binding of the antibody to TADG-15 protein in the sample.
20 Generally, the sample is a biological sample; preferably, the biological sample is from an individual; and typically, the individual is suspected of having cancer.

The present invention is directed toward a kit for detecting TADG-15 mRNA, comprising: an oligonucleotide probe,
25 wherein the probe is specific for TADG-15. The kit may further comprise: a label with which to label the probe; and means for detecting the label. The present invention is additionally directed toward a kit for detecting TADG-15 protein, comprising: an antibody which is specific for TADG-15 protein or a fragment

thereof. The kit may further comprise: means to detect the antibody.

The present invention is directed toward a antibody which is specific for TADG-15 protein or a fragment thereof.

5 The present invention is directed toward a method of screening for compounds that inhibit TADG-15, comprising the steps of: (a) contacting a sample containing TADG-15 protein with a compound; and (b) assaying for TADG-15 protease activity. Typically, a decrease in the TADG-15 protease activity in
10 the presence of the compound relative to TADG-15 protease activity in the absence of the compound is indicative of a compound that inhibits TADG-15.

The present invention is directed toward a method of inhibiting expression of TADG-15 in a cell, comprising the step of:
15 (a) introducing a vector expressing TADG-15 antisense mRNA into a cell, which hybridizes to endogenous TADG-15 mRNA, thereby inhibiting expression of TADG-15 in the cell. Generally, the inhibition of TADG-15 expression is for treating cancer.

The present invention is directed toward a method of
20 inhibiting a TADG-15 protein in a cell, comprising the step of: (a) introducing an antibody specific for a TADG-15 protein or a fragment thereof into a cell, which inhibits the TADG-15 protein. Generally, the inhibition of the TADG-15 protein is for treating cancer.

25 The present invention is directed toward a method of targeted therapy to an individual, comprising the step of: (a) administering a compound having a targeting moiety and a therapeutic moiety to an individual, wherein the targeting moiety is specific for TADG-15. Representative targeting moiety are an

antibody specific for TADG-15 and a ligand or ligand binding domain (*e.g.*, CUB, LDLR, protease and extracellular) that binds TADG-15. Likewise, a representative therapeutic moiety is a radioisotope, a toxin, a chemotherapeutic agent and immune
5 stimulants. Typically, the above-described method is useful when the individual suffers from ovarian cancer, breast cancer or cancers of the prostate, lung, colon and cervix.

The present invention is directed toward a method of diagnosing cancer in an individual, comprising the steps of: (a)
10 obtaining a biological sample from an individual; and (b) detecting TADG-15 in the sample. Generally, the presence of TADG-15 in the sample is indicative of the presence of carcinoma in the individual, and the absence of TADG-15 in the sample is indicative of the absence of carcinoma in the individual.
15 Generally, the biological sample is blood, ascites fluid, urine, tears, saliva or interstitial fluid. Typical means of detecting TADG-15 are by Northern blot, Western blot, PCR, dot blot, ELISA, radioimmunoassay, DNA chips or tumor cell labeling. This method may be useful in diagnosing cancers such as ovarian,
20 breast and other cancers in which TADG-15 is overexpressed, such as lung, prostate and colon cancers.

The present invention is also directed to an antisense oligonucleotide having the nucleotide sequence complementary to a TADG-15 mRNA sequence. The present invention is also
25 directed to a composition comprising such an antisense oligonucleotide according and a physiologically acceptable carrier therefore.

The present invention is also directed to a method of treating a neoplastic state in an individual syndrome in an

individual in need of such treatment, comprising the step of administering to said individual an effective dose of an antisense oligonucleotide of. Preferably, the neoplastic state is selected from the group consisting of from ovarian cancer, breast cancer, lung cancer, prostate cancer, colon cancer and other cancers in which TADG-15 is overexpressed. For such therapy, the oligonucleotides alone or in combination with other anti-neoplastic agents can be formulated for a variety of modes of administration, including systemic, topical or localized administration. Techniques and formulations generally can be found in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, Pa. The oligonucleotide active ingredient is generally combined with a pharmaceutically acceptable carrier such as a diluent or excipient which can include fillers, extenders, binders, wetting agents, disintegrants, surface active agents or lubricants, depending on the nature of the mode of administration and dosage forms. Typical dosage forms include tablets, powders, liquid preparations including suspensions, emulsions, and solutions, granules, capsules and suppositories, as well as liquid preparations for injections, including liposome preparations.

For systemic administration, injection is preferred, including intramuscular, intravenous, intraperitoneal and subcutaneous. For injection, the oligonucleotides of the invention are formulated in liquid solutions, preferably in physiologically compatible buffers. In addition, the oligonucleotides can be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms are also included. Dosages that can be used for systemic administration preferably range from about 0.01 mg/kg to 50

mg/kg administered once or twice per day. However, different dosing schedules can be utilized depending on (1) the potency of an individual oligonucleotide at inhibiting the activity of its target DNA, (2) the severity or extent of the pathological disease state, or (3) the pharmacokinetic behavior of a given oligonucleotide.

The present invention is directed toward a method of vaccinating an individual against TADG-15 overexpression, comprising the steps of: (a) inoculating an individual with a TADG-15 protein or fragment thereof which lacks TADG-15 protease activity. The inoculation with the TADG-15 protein or fragment thereof elicits an immune response in the individual, thereby vaccinating the individual against TADG-15. The vaccination with TADG-15 described herein is intended for an individual who has cancer, is suspected of having cancer or is at risk of getting cancer. Generally, the TADG-15 fragment useful for vaccinating an individual are 9-residue fragments up to 20-residue fragments, with preferred 9-residue fragments shown in SEQ ID Nos. 2, 19, 20, 21, 29, 39, 49, 50, 59, 79, 80, 81, 82, 83, 84, 89 and 90.

The present invention is directed toward a method of producing immune-activated cells directed toward TADG-15, comprising the steps of: exposing dendritic cells to a TADG-15 protein or fragment thereof that lacks TADG-15 protease activity, wherein exposure to the TADG-15 protein or fragment thereof activates the dendritic cells, thereby producing immune-activated cells directed toward TADG-15. Representative immune-activated cells are B-cells, T-cells and dendrites. Generally, the TADG-15 fragment is a 9-residue fragment up to a 20-residue fragment, with preferable 9-residue fragments shown in SEQ ID Nos. 2, 19,

20, 21, 29, 39, 49, 50, 59, 79, 80, 81, 82, 83, 84, 89 and 90. Preferably, the dendritic cells are isolated from an individual prior to exposure, and the activated dendritic cells reintroduced into the individual subsequent to exposure. Typically, the
5 individual for which this method may apply has cancer, is suspected of having cancer or is at risk of getting cancer.

The present invention is directed toward an immunogenic composition, comprising an immunogenic fragment of a TADG-15 protein and an appropriate adjuvant. Generally,
10 the fragment is a 9-residue fragment up to a 20-residue fragment, with preferred 9-residue fragments shown in SEQ ID Nos. 2, 19, 20, 21, 29, 39, 49, 50, 59, 79, 80, 81, 82, 83, 84, 89 and 90.

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and
15 recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, *e.g.*, Maniatis, Fritsch & Sambrook, "Molecular Cloning: A Laboratory Manual (1982); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover ed. 1985); "Oligonucleotide Synthesis" (M.J. Gait ed.
20 1984); "Nucleic Acid Hybridization" (B.D. Hames & S.J. Higgins eds. 1985); "Transcription and Translation" (B.D. Hames & S.J. Higgins eds. 1984); "Animal Cell Culture" (R.I. Freshney, ed. 1986); "Immobilized Cells And Enzymes" (IRL Press, 1986); B. Perbal, "A Practical Guide To Molecular Cloning" (1984).

25 Therefore, if appearing herein, the following terms shall have the definitions set out below.

As used herein, the term "cDNA" shall refer to the DNA copy of the mRNA transcript of a gene.

As used herein, the term "derived amino acid sequence" shall mean the amino acid sequence determined by reading the triplet sequence of nucleotide bases in the cDNA.

As used herein the term "screening a library" shall
5 refer to the process of using a labeled probe to check whether, under the appropriate conditions, there is a sequence complementary to the probe present in a particular DNA library. In addition, "screening a library" could be performed by PCR.

As used herein, the term "PCR" refers to the
10 polymerase chain reaction that is the subject of U.S. Patent Nos. 4,683,195 and 4,683,202 to Mullis, as well as other improvements now known in the art.

The amino acid described herein are preferred to be in the "L" isomeric form. However, residues in the "D" isomeric
15 form can be substituted for any L-amino acid residue, as long as the desired functional property of immunoglobulin-binding is retained by the polypeptide. NH₂ refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxy terminus of a
20 polypeptide. In keeping with standard polypeptide nomenclature, *J Biol. Chem.*, 243:3552-59 (1969), abbreviations for amino acid residues are used as in customary in the art.

It should be noted that all amino-acid residue sequences are represented herein by formulae whose left and
25 right orientation is in the conventional direction of amino-terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino-acid residues.

A "replicon" is any genetic element (*e.g.*, plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication *in vivo*; *i.e.*, capable of replication under its own control.

5 A "vector" is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment. A "vector" may further be defined as a replicable nucleic acid construct, *e.g.*, a plasmid or viral nucleic acid.

10 A "DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its either single-stranded form or as a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary
15 forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear DNA molecules (*e.g.*, restriction fragments), viruses, plasmids, and chromosomes. The structure is discussed herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand
20 of DNA (*i.e.*, the strand having a sequence homologous to the mRNA).

An expression vector is a replicable construct in which a nucleic acid sequence encoding a polypeptide is operably linked to suitable control sequences capable of effecting
25 expression of the polypeptide in a cell. The need for such control sequences will vary depending upon the cell selected and the transformation method chosen. Generally, control sequences include a transcriptional promoter and/or enhancer, suitable mRNA ribosomal binding sites, and sequences which control the

termination of transcription and translation. Methods which are well known to those skilled in the art can be used to construct expression vectors containing appropriate transcriptional and translational control signals. See, for example, techniques
5 described in Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual* (2nd Ed.), Cold Spring Harbor Press, N.Y. A gene and its transcription control sequences are defined as being "operably linked" if the transcription control sequences effectively control transcription of the gene. Vectors of the
10 invention include, but are not limited to, plasmid vectors and viral vectors. Preferred viral vectors of the invention are those derived from retroviruses, adenovirus, adeno-associated virus, SV40 virus, or herpes viruses. In general, expression vectors contain promoter sequences which facilitate the efficient
15 transcription of the inserted DNA fragment and are used in connection with the host. The expression vector typically contains an origin of replication, promoter(s), terminator(s), as well as specific genes which are capable of providing phenotypic selection in transformed cells. The transformed hosts can be
20 fermented and cultured according to means known in the art to achieve optimal cell growth.

An "origin of replication" refers to those DNA sequences that participate in DNA synthesis.

A DNA "coding sequence" is a double-stranded DNA
25 sequence which is transcribed and translated into a polypeptide *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding

sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (*e.g.*, mammalian) DNA, and even synthetic DNA sequences. A polyadenylation signal and
5 transcription termination sequence will usually be located 3' to the coding sequence.

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide
10 for the expression of a coding sequence in a host cell.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter
15 sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site, as
20 well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters often, but not always, contain "TATA" boxes and "CAT" boxes. Prokaryotic promoters typically contain Shine-Dalgarno ribosome-binding sequences in addition to the -10 and -35
25 consensus sequences.

An "expression control sequence" is a DNA sequence that controls and regulates the transcription and translation of another DNA sequence. A coding sequence is "under the control" of transcriptional and translational control sequences in a cell

when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence.

5 A "signal sequence" can be included near the coding sequence. This sequence encodes a signal peptide, N-terminal to the polypeptide, that communicates to the host cell to direct the polypeptide to the cell surface or secrete the polypeptide into the media, and this signal peptide is clipped off by the host cell before the protein leaves the cell. Signal sequences can be found
10 associated with a variety of proteins native to prokaryotes and eukaryotes.

As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.

15 A cell has been "transformed" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA
20 may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the
25 ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A "clone" is a population of cells derived from a single cell or ancestor by mitosis. A "cell line" is a clone

of a primary cell that is capable of stable growth *in vitro* for many generations.

Two DNA sequences are "substantially homologous" when at least about 75% (preferably at least about 80%, and most preferably at least about 90% or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, *e.g.*, Maniatis et al., *supra*; DNA Cloning, Vols. I & II, *supra*; Nucleic Acid Hybridization, *supra*.

A "heterologous" region of the DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. In another example, coding sequence is a construct where the coding sequence itself is not found in nature (*e.g.*, a cDNA where the genomic coding sequence contains introns, or synthetic sequences having codons different than the native gene). Allelic variations or naturally-occurring mutational events do not give rise to a heterologous region of DNA as defined herein.

The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to ultraviolet light, and others. A number of fluorescent materials are known and can be utilized as labels.

These include, for example, fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow. A particular detecting material is anti-rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate. Proteins can also be
5 labeled with a radioactive element or with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The preferred isotope may be selected from ^3H , ^{14}C , ^{32}P , ^{35}S , ^{36}Cl , ^{51}Cr , ^{57}Co , ^{58}Co , ^{59}Fe , ^{90}Y , ^{125}I , ^{131}I , and ^{186}Re . Enzyme labels are likewise useful, and can be detected
10 by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques. The enzyme is conjugated to the selected particle by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes which
15 can be used in these procedures are known and can be utilized. The preferred are peroxidase, β -glucuronidase, β -D-glucosidase, β -D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase. U.S. Patent Nos. 3,654,090, 3,850,752, and 4,016,043 are referred to by way of example for their disclosure
20 of alternate labeling material and methods.

A particular assay system developed and utilized in the art is known as a receptor assay. In a receptor assay, the material to be assayed is appropriately labeled and then certain cellular test colonies are inoculated with a quantity of both the
25 label after which binding studies are conducted to determine the extent to which the labeled material binds to the cell receptors. In this way, differences in affinity between materials can be ascertained.

An assay useful in the art is known as a "cis/trans" assay. Briefly, this assay employs two genetic constructs, one of which is typically a plasmid that continually expresses a particular receptor of interest when transfected into an appropriate cell line, and the second of which is a plasmid that expresses a reporter such as luciferase, under the control of a receptor/ligand complex. Thus, for example, if it is desired to evaluate a compound as a ligand for a particular receptor, one of the plasmids would be a construct that results in expression of the receptor in the chosen cell line, while the second plasmid would possess a promoter linked to the luciferase gene in which the response element to the particular receptor is inserted. If the compound under test is an agonist for the receptor, the ligand will complex with the receptor, and the resulting complex will bind the response element and initiate transcription of the luciferase gene. The resulting chemiluminescence is then measured photometrically, and dose response curves are obtained and compared to those of known ligands. The foregoing protocol is described in detail in U.S. Patent No. 4,981,784.

As used herein, the term "host" is meant to include not only prokaryotes but also eukaryotes such as yeast, plant and animal cells. A recombinant DNA molecule or gene which encodes a human TADG-15 protein of the present invention can be used to transform a host using any of the techniques commonly known to those of ordinary skill in the art. Especially preferred is the use of a vector containing coding sequences for the gene which encodes a human TADG-15 protein of the present invention for purposes of prokaryote transformation. Prokaryotic hosts may include *E. coli*, *S. typhimurium*, *Serratia*

marcescens and *Bacillus subtilis*. Eukaryotic hosts include yeasts such as *Pichia pastoris*, mammalian cells and insect cells.

The invention includes a substantially pure DNA encoding a TADG-15 protein, a DNA strand which will hybridize
5 at high stringency to a probe containing a sequence of at least 15 consecutive nucleotides of (SEQ ID No. 1). The protein encoded by the DNA of this invention may share at least 80% sequence identity (preferably 85%, more preferably 90%, and most preferably 95%) with the amino acids listed in Figures 3 and 4
10 (SEQ ID No. 2). More preferably, the DNA includes the coding sequence of the nucleotides of Figure 2 (SEQ ID No. 1), or a degenerate variant of such a sequence. This invention also includes a substantially pure DNA containing a sequence of at least 15 consecutive nucleotides (preferably 20, more preferably
15 30, even more preferably 50, and most preferably all) of the region from nucleotides 1 to 3147 of the nucleotides shown in Figure 2 (SEQ ID No. 1).

By "substantially pure DNA" is meant DNA that is not part of a milieu in which the DNA naturally occurs, by virtue of
20 separation (partial or total purification) of some or all of the molecules of that milieu, or by virtue of alteration of sequences that flank the claimed DNA. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the
25 genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (*e.g.*, a cDNA or a genomic or cDNA fragment produced by polymerase chain reaction (PCR) or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene

encoding additional polypeptide sequence, *e.g.*, a fusion protein. Also included is a recombinant DNA which includes a portion of the nucleotides listed in Figure 2 (SEQ ID No. 1) and which encodes an alternative splice variant of TADG-15.

5 By a "substantially pure protein" is meant a protein which has been separated from at least some of those components which naturally accompany it. Typically, the protein is substantially pure when it is at least 60% (by weight) free from the proteins and other naturally-occurring organic molecules
10 with which it is naturally associated *in vivo*. Preferably, the purity of the preparation (by weight) is at least 75%, more preferably at least 90%, and most preferably at least 99%. A substantially pure TADG-15 protein may be obtained, for example, by extraction from a natural source; by expression of a recombinant nucleic
15 acid encoding a TADG-15 polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, *e.g.*, column chromatography, such as immunoaffinity chromatography using an antibody specific for TADG-15, polyacrylamide gel electrophoresis, or HPLC analysis. A
20 protein is substantially free of naturally associated components when it is separated from at least some of those contaminants which accompany it in its natural state. Thus, a protein which is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates will be, by
25 definition, substantially free from its naturally associated components. Accordingly, substantially pure proteins include eukaryotic proteins synthesized in *E. coli*, other prokaryotes, or any other organism in which they do not naturally occur.

The term "oligonucleotide", as used herein, is defined as a molecule comprised of two or more ribonucleotides, preferably more than three. Its exact size will depend upon many factors, which, in turn, depend upon the ultimate function and use of the oligonucleotide. The term "primer", as used herein, refers to an oligonucleotide, whether occurring naturally (as in a purified restriction digest) or produced synthetically, and which is capable of initiating synthesis of a strand complementary to a nucleic acid when placed under appropriate conditions, *i.e.*, in the presence of nucleotides and an inducing agent, such as a DNA polymerase, and at a suitable temperature and pH. The primer may be either single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, sequence and/or homology of primer and the method used. For example, in diagnostic applications, the oligonucleotide primer typically contains 15-25 or more nucleotides, depending upon the complexity of the target sequence, although it may contain fewer nucleotides.

The primers herein are selected to be "substantially" complementary to particular target DNA sequences. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment (*i.e.*, containing a restriction site) may be attached to the 5' end of the primer, with the remainder of the primer sequence being complementary to the strand. Alternatively, non-complementary bases or longer

sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence to hybridize therewith and form the template for synthesis of the extension product.

5 The probe to which the DNA of the invention hybridizes preferably consists of a sequence of at least 20 consecutive nucleotides, more preferably 40 nucleotides, even more preferably 50 nucleotides, and most preferably 100 nucleotides or more (up to 100%) of the coding sequence of the
10 nucleotides listed in Figure 2 (SEQ ID No. 1) or the complement thereof. Such a probe is useful for detecting expression of TADG-15 in a cell by a method including the steps of (a) contacting mRNA obtained from the cell with a labeled TADG-15 hybridization probe; and (b) detecting hybridization of the probe
15 with the mRNA.

 By "high stringency" is meant DNA hybridization and wash conditions characterized by high temperature and low salt concentration, *e.g.*, wash conditions of 65°C at a salt concentration of approximately 0.1X SSC, or the functional
20 equivalent thereof. For example, high stringency conditions may include hybridization at about 42°C in the presence of about 50% formamide; a first wash at about 65°C with about 2X SSC containing 1% SDS; followed by a second wash at about 65°C with about 0.1X SSC.

25 The DNA may have at least about 70% sequence identity to the coding sequence of the nucleotides listed in Figure 2 (SEQ ID No. 1), preferably at least 75% (*e.g.*, at least 80%); and most preferably at least 90%. The identity between two sequences is a direct function of the number of matching or

identical positions. When a position in both of the two sequences is occupied by the same monomeric subunit, *e.g.*, if a given position is occupied by an adenine in each of two DNA molecules, then they are identical at that position. For example, if
5 7 positions in a sequence 10 nucleotides in length are identical to the corresponding positions in a second 10-nucleotide sequence, then the two sequences have 70% sequence identity. The length of comparison sequences will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more
10 preferably at least 75 nucleotides, and most preferably 100 nucleotides. Sequence identity is typically measured using sequence analysis software (*e.g.*, Sequence Analysis Software Package of the Genetics Computer Group (GCG), University of Wisconsin Biotechnology Center, 1710 University Avenue,
15 Madison, WI 53705).

The present invention comprises a vector comprising a DNA sequence which encodes a human TADG-15 protein, wherein said vector is capable of replication in a host, and comprises, in operable linkage: a) an origin of replication; b) a
20 promoter; and c) a DNA sequence coding for said TADG-15 protein. Preferably, the vector of the present invention contains a portion of the DNA sequence shown in SEQ ID No. 1. Vectors may be used to amplify and/or express nucleic acid encoding a TADG-15 protein or fragment thereof.

25 In addition to substantially full-length proteins, the invention also includes fragments (*e.g.*, antigenic fragments) of the TADG-15 protein (SEQ ID No. 2). As used herein, "fragment," as applied to a polypeptide, will ordinarily be at least 6 residues, more typically at least 9-12 residues, and preferably at least 13-

20 residues in length, but less than the entire, intact sequence. Alternatively, a fragment may be an individual domain of 20-120 residues from SEQ ID No. 2. Fragments of the TADG-15 protein can be generated by methods known to those skilled in the art, 5 *e.g.*, by enzymatic digestion of naturally occurring or recombinant TADG-15 protein, by recombinant DNA techniques using an expression vector that encodes a defined fragment of TADG-15, or by chemical synthesis. The ability of a candidate fragment to exhibit a characteristic of TADG-15 (*e.g.*, binding to 10 an antibody specific for TADG-15) can be assessed by methods described herein. Purified TADG-15 or antigenic fragments of TADG-15 can be used to generate new antibodies or to test existing antibodies (*e.g.*, as positive controls in a diagnostic assay) by employing standard protocols known to those skilled in 15 the art. Included in this invention is polyclonal antisera generated by using TADG-15 or a fragment of TADG-15 as the immunogen in, *e.g.*, rabbits. Standard protocols for monoclonal and polyclonal antibody production known to those skilled in this art are employed. The monoclonal antibodies generated by this 20 procedure can be screened for the ability to identify recombinant TADG-15 cDNA clones, and to distinguish them from other cDNA clones.

Further included in this invention are TADG-15 proteins which are encoded, at least in part, by portions of SEQ ID 25 No. 2, *e.g.*, products of alternative mRNA splicing or alternative protein processing events, or in which a section of TADG-15 sequence has been deleted. The fragment, or the intact TADG-15 polypeptide, may be covalently linked to another polypeptide,

e.g., one which acts as a label, a ligand or a means to increase antigenicity.

The invention also includes a polyclonal or monoclonal antibody which specifically binds to TADG-15. The invention encompasses not only an intact monoclonal antibody, but also an immunologically-active antibody fragment, *e.g.*, a Fab or (Fab)₂ fragment; an engineered single chain Fv molecule; or a chimeric molecule, *e.g.*, an antibody which contains the binding specificity of one antibody, *e.g.*, of murine origin, and the remaining portions of another antibody, *e.g.*, of human origin.

In one embodiment, the antibody, or a fragment thereof, may be linked to a toxin or to a detectable label, *e.g.*, a radioactive label, non-radioactive isotopic label, fluorescent label, chemiluminescent label, paramagnetic label, enzyme label, or colorimetric label. Examples of suitable toxins include diphtheria toxin, *Pseudomonas* exotoxin A, ricin, and cholera toxin. Examples of suitable enzyme labels include malate hydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, alcohol dehydrogenase, alpha-glycerol phosphate dehydrogenase, triose phosphate isomerase, peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase, acetylcholinesterase, etc. Examples of suitable radioisotopic labels include ³H, ¹²⁵I, ¹³¹I, ³²P, ³⁵S, ¹⁴C, etc.

Paramagnetic isotopes for purposes of *in vivo* diagnosis can also be used according to the methods of this invention. There are numerous examples of elements that are useful in magnetic resonance imaging. For discussions on *in vivo* nuclear magnetic resonance imaging, see, for example, Schaefer

et al., (1989) *JACC* 14, 472-480; Shreve et al., (1986) *Magn. Reson. Med.* 3, 336-340; Wolf, G. L., (1984) *Physiol. Chem. Phys. Med. NMR* 16, 93-95; Wesbey et al., (1984) *Physiol. Chem. Phys. Med. NMR* 16, 145-155; Runge et al., (1984) *Invest. Radiol.* 19, 408-415. Examples of suitable fluorescent labels include a fluorescein label, an isothiocyalate label, a rhodamine label, a phycoerythrin label, a phycocyanin label, an allophycocyanin label, an ophthaldehyde label, a fluorescamine label, etc. Examples of chemiluminescent labels include a luminal label, an isoluminal label, an aromatic acridinium ester label, an imidazole label, an acridinium salt label, an oxalate ester label, a luciferin label, a luciferase label, an aequorin label, etc.

Those of ordinary skill in the art will know of other suitable labels which may be employed in accordance with the present invention. The binding of these labels to antibodies or fragments thereof can be accomplished using standard techniques commonly known and used by those of ordinary skill in the art. Typical techniques are described by Kennedy et al., (1976) *Clin. Chim. Acta* 70, 1-31; and Schurs et al., (1977) *Clin. Chim. Acta* 81, 1-40. Coupling techniques mentioned in the latter are the glutaraldehyde method, the periodate method, the dimaleimide method, the m-maleimidobenzyl-N-hydroxy-succinimide ester method.

Also within the invention is a method of detecting TADG-15 protein in a biological sample, which includes the steps of contacting the sample with the labeled antibody, *e.g.*, radioactively tagged antibody specific for TADG-15, and determining whether the antibody binds to a component of the

sample. Antibodies to the TADG-15 protein can be used in an immunoassay to detect increased levels of TADG-15 protein expression in tissues suspected of neoplastic transformation. These same uses can be achieved with Northern blot assays and
5 analyses.

As described herein, the invention provides a number of diagnostic advantages and uses. For example, the TADG-15 protein is useful in diagnosing cancer in different tissues since this protein is highly overexpressed in tumor cells. Antibodies
10 (or antigen-binding fragments thereof) which bind to an epitope specific for TADG-15, are useful in a method of detecting TADG-15 protein in a biological sample for diagnosis of cancerous or neoplastic transformation. This method includes the steps of obtaining a biological sample (*e.g.*, cells, blood, plasma, tissue,
15 etc.) from a patient suspected of having cancer, contacting the sample with a labeled antibody (*e.g.*, radioactively tagged antibody) specific for TADG-15, and detecting the TADG-15 protein using standard immunoassay techniques such as an ELISA. Antibody binding to the biological sample indicates that the
20 sample contains a component which specifically binds to an epitope within TADG-15.

Likewise, a standard Northern blot assay can be used to ascertain the relative amounts of TADG-15 mRNA in a cell or tissue obtained from a patient suspected of having cancer, in
25 accordance with conventional Northern hybridization techniques known to those of ordinary skill in the art. This Northern assay uses a hybridization probe, *e.g.*, radiolabelled TADG-15 cDNA, either containing the full-length, single stranded DNA having a sequence complementary to SEQ ID No. 1 (Figure 2), or a

fragment of that DNA sequence at least 20 (preferably at least 30, more preferably at least 50, and most preferably at least 100 consecutive nucleotides in length). The DNA hybridization probe can be labeled by any of the many different methods known to those skilled in this art.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.

10

EXAMPLE 1

Tissue collection and storage

Upon patient hysterectomy, bilateral salpingo-oophorectomy, or surgical removal of neoplastic tissue, the specimen is retrieved and placed on ice. The specimen was then taken to the resident pathologist for isolation and identification of specific tissue samples. Finally, the sample was frozen in liquid nitrogen, logged into the laboratory record and stored at -80°C.

Additional specimens were frequently obtained from the Cooperative Human Tissue Network (CHTN). These samples were prepared by the CHTN and shipped on dry ice. Upon arrival, these specimens (*e.g.*, blood (serum), urine, saliva, tears and interstitial fluid) were logged into the laboratory record and stored at -80°C. Participation of the following divisions of the Cooperative Human Tissue Network (CHTN) in providing tumor tissues is acknowledged: Western Division, Case Western Reserve University, (Cleveland, OH); Midwestern Division, Ohio state University, (Columbus, OH); Eastern Division, NDRI, (Philadelphia,

PA); Pediatric Division, Children's Hospital, (Columbus, OH); Southern Division, University of Alabama at Birmingham, (Birmingham, AL).

EXAMPLE 2

5 mRNA isolation and cDNA synthesis

Forty-one ovarian tumors (10 low malignant potential tumors and 31 carcinomas) and 10 normal ovaries were obtained from surgical specimens and frozen in liquid nitrogen. The human ovarian carcinoma cell lines SW626 and CAOV3, and the
10 human breast carcinoma cell lines MDA-MB-231 and MDA-MB-435S, were purchased from the American Type Culture Collection (Rockville, MD). Cells were cultured to sub-confluency in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum and antibiotics.

15 Messenger RNA (mRNA) isolation was performed according to the manufacturer's instructions using the Mini RiboSepTM Ultra mRNA Isolation Kit purchased from Becton Dickinson. In this procedure, polyA⁺ mRNA was isolated directly from the tissue lysate using the affinity chromatography media
20 oligo(dT) cellulose. The amount of mRNA recovered was quantitated by UV spectrophotometry.

First-strand complementary DNA (cDNA) was synthesized using 5.0 µg of mRNA and either random hexamer or oligo(dT) primers according to the manufacturer's protocol
25 utilizing a first strand synthesis kit obtained from CLONTECH (Palo Alto, CA). The purity of the cDNA was evaluated by PCR using primers specific for the p53 gene. These primers span an intron such that pure cDNA can be distinguished from cDNA that is contaminated with genomic DNA.

EXAMPLE 3

PCR with redundant primers, cloning of TADG-15 cDNA, T-vector ligation and transformations and DNA sequencing

Redundant primers,

5 forward 5'-TGGGTIGTIACIGCIGCICA(C/T)TG-3' (SEQ ID No. 11) and reverse 5'-A(A/G)IGGICCCICCI(C/G)(T/A)(A/G)TCICC-3' (SEQ ID No. 12), corresponding to the amino acids surrounding the catalytic triad for serine proteases, were used to compare the PCR products from normal and carcinoma cDNAs.

10 The purified PCR products were ligated into the Promega T-vector plasmid and the ligation products used to transform JM109 competent cells according to the manufacturer's instructions (Promega). Positive colonies were cultured for amplification, the plasmid DNA isolated using the
15 WizardTM Minipreps DNA purification system (Promega), and the plasmids were digested with *Apa*I and *Sac*I restriction enzymes to determine the size of the insert. Plasmids with inserts of the size(s) visualized by the previously described PCR product gel electrophoresis were sequenced.

20 Individual colonies were cultured and plasmid DNA was isolated using the Wizard Miniprep DNA purification system (Promega). Applied Biosystems Model 373A DNA sequencing system was used for direct cDNA sequence determination. Utilizing a plasmid-specific primer near the cloning site,
25 sequencing reactions were carried out using PRISMTM Ready Reaction Dye DeoxyTM terminators (Applied Biosystems) according to the manufacturer's instructions. Residual dye terminators were removed from the completed sequencing reaction using a Centri-sepTM spin column (Princeton Separation).

Based upon the determined sequence, primers that specifically amplify the gene of interest were designed and synthesized.

The original TADG-15 subclone (436bp) was randomly labeled and used as a probe to screen an ovarian tumor cDNA library by standard hybridization techniques.¹³ The library was constructed in 8ZAP using mRNA isolated from the tumor cells of a stage III/grade III ovarian adenocarcinoma patient. Three overlapping clones were obtained which spanned 3147 nucleotides.

10

EXAMPLE 4

Northern blot analysis

10 µg mRNAs were size separated by electrophoresis through a 1% formaldehyde-agarose gel in 0.02 M MOPS, 0.05 M sodium acetate (pH 7.0), and 0.001 M EDTA. The mRNAs were then blotted to Hybond-N⁺ nylon membrane (Amersham) by capillary action in 20x SSPE. The RNAs are fixed to the membrane by baking for 2 hours at 80°C. ³²P-labeled cDNA probes were made by Prime-a-Gene^{*} Labeling System (Promega). The PCR products amplified by the same primers described above were used for probes. The blots were prehybridized for 30 min and hybridized for 60 min at 68°C with ³²P-labeled cDNA probe in ExpressHyb^{*} Hybridization Solution (CLONTECH). Control hybridization to determine relative gel loading was performed with a β-tubulin probe.

25

Normal human tissues; spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocyte, and normal human fetal tissues; brain, lung, liver and kidney (Human Multiple Tissue Northern Blot; CLONTECH) were also examined by the same hybridization procedure. Additional

*Trade-mark

multiple tissue northern (MTN) blots from CLONTECH include the Human MTN blot, the Human MTN II blot, the Human Fetal MTN II blot, and the Human Brain MTN III blot.

5

EXAMPLE 5

Western blot analysis

Polyclonal rabbit antibody was generated by immunization with a poly-lysine linked multiple Ag peptide derived from the TADG-15 protein sequence 'LFRDWIKENTGV' (SEQ ID No. 13). Approximately 20 µg of cell lysates were separated on a 15% SDS-PAGE gel and electroblotted to PVDF at 100 V for 40 min at 4°C. The proteins were fixed to the membrane by incubation in 50% MeOH for 10 min. The membrane was blocked overnight in TBS (pH 7.8) containing 0.2% non-fat milk. Primary antibody was added to the membrane at a dilution of 1:100 in 0.2% milk/TBS and incubated for 2 h at room temperature. The blot was washed and incubated with a 1:3000 dilution of alkaline-phosphatase conjugated goat anti-rabbit IgG (BioRad) for 1 h at room temperature. The blot was washed and incubated with a chemiluminescent substrate before a 10 sec exposure to X-ray film for visualization.

EXAMPLE 6

Quantitative PCR

The mRNA overexpression of TADG-15 was determined using a quantitative PCR. Quantitative PCR was performed.^{11,12} Oligonucleotide primers were used for TADG-15: forward 5'-ATGACAGAGGATTCAGGTAC-3' (SEQ ID No. 14) and

reverse 5'-GAAGGTGAAGTCATTGAAGA-3' (SEQ ID No. 15);
and and for β -tubulin:

forward 5'-CGCATCAACGTGTACTACAA-3' (SEQ ID No. 16)
and reverse 5'-TACGAGCTGGTGGACTGAGA-3' (SEQ ID No. 17).

5 β -tubulin was utilized as an internal control.

The PCR reaction mixture consists of cDNA derived from 50 ng of mRNA, 5 pmol of sense and antisense primers for both the TADG-15 gene and the β -tubulin gene, 200 μ mol of dNTPs, 5 μ Ci of α -³²PdCTP and 0.25 units of Taq DNA polymerase
10 with reaction buffer (Promega) in a final volume of 25 μ l. The target sequences were amplified in parallel with the β -tubulin gene. Thirty cycles of PCR were carried out in a Thermal Cycler (Perkin Elmer Gene Amp 2400; Perkin-Elmer Cetus). Each cycle of PCR included 30 sec of denaturation at 94°C, 30 sec of annealing
15 at 60°C and 30 sec of extension at 72°C. The annealing temperature varies according to the primers that are used in the PCR reaction. For the reactions involving degenerate primers, an annealing temperature of 48°C was used. The appropriate annealing temperature for the TADG-15- and β -tubulin-specific
20 primers is 62°C.

A portion of the PCR products were separated on 2% agarose gels and the radioactivity of each PCR product was determined by using a PhosphoImager (Molecular Dynamics). In the present study, the expression ratio (TADG-15/ β -tubulin) was
25 used to evaluate gene expression and defined the value at mean $\pm$ 2SD of normal ovary as the cut-off value to determine overexpression. The student's *t* test was used for comparison of the mean values of normal ovary and tumors.

EXAMPLE 7

Immunohistochemistry

Immunohistochemical staining was performed using a Vectastain Elite ABC Kit (Vector). Formalin-fixed and paraffin-
5 embedded specimens were routinely deparaffinized and processed using microwave heat treatment in 0.01 M sodium citrate buffer (pH 6.0). The specimens were incubated with normal goat serum in a moist chamber for 30 min. After incubation with biotinylated anti-rabbit IgG for 30 min, the
10 sections were then incubated with ABC reagent (Vector) for 30 min. The final products were visualized using the AEC substrate system (DAKO) and sections were counterstained with hematoxylin before mounting. Negative controls were performed using normal serum instead of the primary antibody.

15

EXAMPLE 8

Antisense TADG-15

TADG-15 is cloned and expressed in the opposite orientation such that an antisense RNA molecule (SEQ ID No. 18)
20 is produced. For example, the antisense RNA is used to hybridize to the complementary RNA in the cell and thereby inhibit translation of TADG-15 RNA into protein.

EXAMPLE 9

25 Peptide ranking

For vaccine or immune stimulation, individual 9-mers to 11-mers were examined to rank the binding of individual peptides to the top 8 haplotypes in the general population (Parker et al., (1994)).

Table 1 shows the peptide ranking based upon the predicted half-life of each peptide's binding to a particular HLA allele. A larger half-life indicates a stronger association with that peptide and the particular HLA molecule. The TADG-15 peptides that strongly bind to an HLA allele are putative immunogens, and are used to inoculate an individual against TADG-15.

TABLE 1TADG-15 peptide ranking

	HLA Type			Predicted	SEQ
5	& Ranking	Start	Peptide	Dissociation _{1/2}	ID No.
	HLA A0201				
	1	68	VLLGIGFLV	2537.396	19
	2	126	LLYSGVPFL	1470.075	20
10	3	644	SLISPNWLV	521.640	21
	4	379	KVSFKFFYL	396.525	22
	5	386	YLLEPGVPA	346.677	23
	6	257	SLTFRSFDL	123.902	24
	7	762	ILQKGEIRV	118.238	25
15	8	841	RLPLFRDWI	106.842	26
	9	64	GLLLVLLGI	88,783	27
	10	57	VLA AVLIGL	83.527	28
	HLA A0205				
	1	67	LVLLGIGFL	142.800	29
20	2	379	KVSFKFFYL	100.800	30
	3	126	LLYSGVPFL	71.400	31
	4	88	KVFNGYMRI	36.000	32
	5	670	TQWTAFLGL	33.600	33
	6	119	KVKDALKLL	25.200	34
25	7	60	AVLIGLLL	24.000	35
	8	62	LIGLLL	23.800	36
	9	57	VLA AVLIGL	23.800	37
	10	61	VLIGLLL	23.800	38
	HLA A1				
30	1	146	FSEGSVIAY	337.500	39
	2	658	YIDDRGFRY	125.000	40
	3	449	SSDPCPGQF	75.000	41

WO 01/29056

PCT/US00/29095

	4	401	YVEINGEKY 45.000	42
	5	387	LLEPGVPAG 18.000	43
	6	553	GSDEASCPK 15.000	44
	7	97	TNENFVDAY 11.250	45
5	8	110	STEFVSLAS 11.250	46
	9	811	SVEADGRIF 9.000	47
	10	666	YSDPTQWTA 7.500	48
HLA A24				
	1	709	DYDIALLEL 220.000	49
10	2	408	KYCGERSQF 200.000	50
	3	754	QYGGTGALI 50.000	51
	4	153	AYYWSEFSI 50.000	52
	5	722	EYSSMVRPI 50.000	53
	6	326	GFEATFFQL 36.000	54
15	7	304	TFHSSQNVL 24.000	55
	8	707	TFDYDIALL 20.000	56
	9	21	KYNSRHEKV 16.500	57
	10	665	RYSDPTQWT 14.400	58
HLA B7				
20	1	686	APGVQERRL 240.000	59
	2	12	GPKDFGAGL 80.000	60
	3	668	DPTQWTAFL 80.000	61
	4	461	TGRCIRKEL 60.000	62
	5	59	AAVLIGLLL 36.000	63
25	6	379	KVSFKFFYL 20.000	64
	7	119	KVKDALKLL 20.000	65
	8	780	LPQQITPRM 20.000	66
	9	67	LVLLGIGFL 20.000	67
	10	283	SPMEPHALV 18.000	68
30	HLA B8			
	1	12	GPKDFGAGL 24.000	69
	2	257	SLTFRSFDL 8.000	70

WO 01/29056

PCT/US00/29095

	3	180	MLPPRARSL	8.000	71
	4	217	GLHARGVEL	8.000	72
	5	173	MAEERVVML	4.800	73
	6	267	SCDERGSDL	4.800	74
5	7	567	CTKHTYRCL	4.000	75
	8	724	SSMVRPICL	4.000	76
	9	409	YCGERSQFV	3.600	77
	10	495	TCKNKFCKP	3.200	78
10	HLA B2702				
	1	427	VRFHSDQSY	1000.000	79
	2	695	KRIISHPFF	600.000	80
	3	664	FRYSDPTQW	500.000	81
	4	220	ARGVELMRF	200.000	82
15	5	492	HQFTCKNKF	100.000	83
	6	53	GRWVVLAAV	100.000	84
	7	248	LRGDADSVL	60.000	85
	8	572	YRCLNGLCL	60.000	86
	9	692	RRLKRIISH	60.000	87
20	10	24	SRHEKVNGL	60.000	88
	HLA B4403				
	1	147	SEGSVIAYY	360.000	89
	2	715	LELEKPAEY	360.000	90
	3	105	YENSNSTEF	60.000	91
25	4	14	KDFGAGLKY	50.625	92
	5	129	SGVPFLGPY	36.000	93
	6	436	TDTGFLAEY	33.750	94
	7	766	GEIRVINQT	30.000	95
	8	402	VEINGEKYC	30.000	96
30	9	482	DELNCSCDA	24.000	97
	10	82	RDVRVQKVF	22.500	98

EXAMPLE 10**TADG-15 cDNA**

A screening strategy to identify proteases which are overexpressed in human cancer has been developed in which RT-PCR products amplified specifically in tumors, as compared to normal tissue, are examined.⁹ During this effort, candidate genes were identified using redundant sense primers to the conserved amino acid histidine domain at the NH₃ end of the catalytic domain and antisense primers to the downstream conserved amino acid serine domain. Subcloning and sequencing the appropriate 480 base pair band(s) amplified in such a PCR reaction provides the basis for identifying the gene(s) encoding proteases(s). Among these amplified catalytic domains, a new serine protease gene named TADG-15 (tumor antigen-derived gene 15) was identified. The catalytic domain of the newly identified TADG-15 protein is similar to other serine proteases and specifically contains conserved amino acids appropriate for the catalytic domain of the trypsin-like serine protease family.

A computerized search of GenEMBL databases using the FASTA program (Wisconsin Package Version 9.1, GCG, Madison, Wisconsin) for amino acid sequences homologous to the TADG-15 protease domain revealed that homologies with other known human proteases never exceeds 55%. Figure 1 shows the alignment of the protease domain of TADG-15 compared with other human serine proteases. Using the BESTFIT program available through GCG, the similarities between TADG-15 and trypsin, chymotrypsin, and tissue-type plasminogen activator are 51%, 46% and 52%, respectively.

From the sequence derived from the TADG-15 catalytic domain, specific primers were synthesized to amplify a TADG-15-specific probe for library screening. After screening an ovarian carcinoma library, one 1785 bp clone was obtained which
5 included the 3' end of the TADG-15 transcript. Upon further screening using the 5' end of the newly detected clone, two additional clones were identified which provided another 1362 bp of the cDNA, including the 5' end of the TADG-15 transcript. The total length of the sequenced cDNA was approximately 3.15 kb.
10 The total nucleotide sequence obtained includes a Kozak's consensus sequence preceding a single open reading frame encoding a predicted protein of 855 amino acids (Figure 2).

The deduced open reading frame encoded by the TADG-15 nucleotide sequence (Figures 2, 3 and 4) contains
15 several distinct domains as follows: an amino terminal cytoplasmic tail (amino acids (aa) #1-54), a potential transmembrane domain (aa #55-77), an extracellular membrane domain (aa #78-213), two complement subcomponents C1r/C1s, Uegf, and bone morphogenetic protein 1 (CUB) repeats (aa #214-
20 447), four ligand binding repeats of the low density lipoprotein (LDL) receptor-like domain (aa #453-602) and a serine protease domain (aa #615-855). The TADG-15 protein also contains two potential N-linked glycosylation sites (aa #109 and 302) and a potential proteolytic cleavage site upstream from the protease
25 domain (aa #614) which could release and/or activate the protease at the carboxy end of this protein. In addition, TADG-15 contains an RGD motif (aa #249-251) which is commonly found in proteins involved in cell-cell adhesion.

EXAMPLE 11

TADG-15 expression

To examine the size of the transcript for TADG-15 and its pattern of expression in various tissues, Northern blot hybridization was performed for representative histological types of carcinoma and in a series of cell lines, fetal tissues and normal adult tissues (Figure 5). The transcript size for the TADG-15 message was determined to be approximately 3.2 kb and a single intense transcript appeared to be present in all of the carcinomas examined, whereas no visible band was detected in normal ovary (Figure 5). This transcript size is also in good agreement with the sequence data predicting a transcript size of 3.15 kb. The ovarian tumor cell lines, SW626 and CAOV3, also showed an abundance of transcript, however little or no transcript was detectable in the breast carcinoma cell lines MDA-MB-231 and MDA-MB-4355. Among normal human fetal tissues, fetal kidney showed an abundance of the TADG-15 transcript and low expression was also detected in fetal lung. In normal adult tissues, TADG-15 was detected in colon with low levels of expression in small intestine and prostate (Figure 5).

To evaluate mRNA transcript expression of TADG-15 in ovarian tumors and normal ovary, semi-quantitative PCR (Figure 6) was performed. In a preliminary study, the linearity of this assay^{11,12} was confirmed and its efficacy correlated with both Northern blots and immunohistochemistry. The data was quantified using a phosphoimager and compared as a ratio of expression (TADG-15/ β -tubulin). Results herein indicate that TADG-15 transcript expression is elevated above the cut-off value (mean for normal ovary $\pm$ 2 SD) in all of the tumor cases

examined and is either not detected or detected at extremely low levels in normal ovaries (Figure 6A and B). Analysis of ovarian carcinoma subtypes, including early stage and late stage disease, confirms overexpression of TADG-15 in all carcinomas examined
5 (Table 2). All of the carcinomas studied, which included 5 stage I and 3 stage II carcinomas, showed overexpression of the TADG-15 gene.

These data can also be examined with regard to tumor stage and histological sub-type, and results indicated that every
10 carcinoma of every stage and histological sub-type overexpressed the TADG-15 gene. The expression ratio (mean value $\pm$ SD) for normal ovary group was determined as 0.182 ± 0.024 , for LMP tumor group as 0.847 ± 0.419 and for carcinoma group as 0.771 ± 0.380 (Table 2). A comparison between the normal ovary
15 group and tumor groups showed that overexpression of the TADG-15 gene is statistically significant in both the LMP tumor group and the carcinoma group (LMP tumor: $p < 0.001$, carcinoma: $p < 0.0001$).

As shown in Figure 6, TADG-15 transcripts were noted
20 in all ovarian carcinomas, but were not present at detectable levels in any of the following tissues: a) normal ovary, b) fetal liver and brain, c) adult spleen, thymus, testes, ovary and peripheral blood lymphocytes, d) skeletal muscle, liver, brain or heart. This evaluation was extended to a standard panel of about
25 40 tumors. Using TADG-15-specific primers, the expression was also examined in tumor cell lines derived from both ovarian and breast carcinoma tissues as shown in Figure 7 and in other tumor tissues as shown in Figure 8. Expression of TADG-15 was also observed in carcinomas of the breast, colon, prostate and lung.

Polyclonal antibodies developed to a synthetic peptide (a 12-mer) at the carboxy terminus of the protease domain were used to examine TADG-15 expression in cell lines by Western blot and by immunolocalization in normal ovary and ovarian tumors.

5 Western blots of cell extracts from SW626 and CAOV3 cells were probed with both antibody and preimmune sera (Figure 9). Several bands were detected with the antibody, including bands of approximately 100,000 daltons, approximately 60,000 daltons and 32,000 daltons. The anticipated molecular size of the
10 complete TADG-15 molecule is estimated to be approximately 100,000 daltons, and the protease domain which may be released by proteolytic cleavage at aa #614 is estimated to be approximately 32,000 daltons. Some intermediate proteolytic product may be represented by the 60,000 dalton band.

15 Antibody staining of tumor cells confirms the presence of the TADG-15 protease in the cytoplasm of a serous LMP tumor, mucinous LMP tumor and serous carcinoma (Figure 10B, C & D, respectively). This diffuse staining pattern may be due to detection of TADG15 within the cell as it is being packaged
20 and transported to the cell surface. In endometrioid carcinoma, the antigen is clearly detectable on the surface of tumor cells (Figure 10E). No staining was detected in normal ovarian epithelium or stromal cells (Figure 10A). Immunohistochemical staining of a series of 27 tumors indicates the presence of the
25 TADG-15 protein in all the carcinoma subtypes examined, including the low malignant potential group. Strong staining was noted in 7 of 9 low malignant potential tumors and 13 of 18 carcinomas (Table 3).

TABLE 2

Number of cases with overexpression of TADG-15 in normal ovaries and ovarian tumors

5		N	overexpression	<u>expression ratio^a</u>
			<u>of TADG-15</u>	
	Normal	10	0 (0%)	0.182 ± 0.024
	LMP	10	10 (100%)	0.847 ± 0.419
	serous	6	6 (100%)	0.862 ± 0.419
10	mucinous	4	4 (100%)	0.825 ± 0.483
	Carcinoma	31	31 (100%)	0.771 ± 0.380
	serous	18	18 (100%)	0.779 ± 0.332
	mucinous	7	7 (100%)	0.907 ± 0.584
	endometrioid	3	3 (100%)	0.502 ± 0.083
15	<u>clear cell</u>	<u>3</u>	<u>3 (100%)</u>	<u>0.672 ± 0.077</u>

^aThe ratio of expression level of TADG-15 to β -tubulin (mean ± SD)

TABLE 3Immunohistochemical staining using TADG-15

	<u>Lab No.</u>	<u>Histology</u>	<u>TADG-15</u>
5		Surface epithelium of the ovary	—
	H-3194	serous (LMP)	++
	H-162	serous (LMP)	++
	H-1182	serous (LMP)	++
	H-4818	serous (LMP)	++
10	H-4881	serous (LMP)	++
	H-675	mucinous (LMP)	+
	H-2446	mucinous (LMP)	+
	H-0707	mucinous (LMP)	++
	H-2042	mucinous (LMP)	++
15	H-2555	serous carcinoma	++
	H-1858	serous carcinoma	++
	H-5266	serous carcinoma	++
	H-5316	serous carcinoma	+
	H-2597	serous carcinoma	+
20	H-4931	mucinous carcinoma	++
	H-1867	mucinous carcinoma	++
	H-5998	mucinous carcinoma	++
	H-2679	endometrioid adenocarcinoma	+
	H-5718	endometrioid adenocarcinoma	++
25	H-3993	endometrioid adenocarcinoma	+
	H-2991	endometrioid adenocarcinoma	++
	H-2489	endometrioid adenocarcinoma	++
	H-5994	clear cell carcinoma	++
	H-6718	clear cell carcinoma	++

H-1661	clear cell carcinoma	++
H-6201	clear cell carcinoma	++
<u>H-5640</u>	<u>clear cell carcinoma</u>	<u>+</u>

- Negative; + Weak Positive; ++ Strong Positive (more than 50%
5 of cell staining)

EXAMPLE 12

10 TADG-15 homology

Recently, a mouse protein named epithin (GenBank Accession No. AF042822) has been described.¹⁴ Epithin is a 902 amino acid protein which contains a similar structure to TADG-15 in that it has a cytoplasmic domain, transmembrane domain, two
15 CUB domains, four LDLR-like domains and a carboxy terminal serine protease domain. TADG-15 and epithin are 84% similar over 843 amino acids, suggesting that the proteins may be orthologous (Figure 11). The precise role of epithin remains to be elucidated.

20 A search of GeneBank for similar previously identified sequences yielded one such sequence with relatively high homology to a portion of the TADG-15 gene. The similarity between the portion of TADG-15 from nucleotide #182 to 3139 and SNC-19 GeneBank Accession No. #U20428) is approximately
25 97% (Figure 12). There are however significant differences between SNC-19 and TADG-15. For example, TADG-15 has an open reading frame of 855 amino acids whereas the longest open reading frame of SNC-19 is 173 amino acids. Additionally, SNC-19 does not include a proper start site for the initiation of

translation, nor does it include the amino terminal portion of the protein encoded by TADG-15. Moreover, SNC-19 does not include an open reading frame for a functional serine protease because the His, Asp and Ser residues of the catalytic triad that
5 are necessary for function are encoded in different reading frames.

Implications

The overall structure of the TADG-15 protein is
10 relatively similar to the members of the tolloid/BMP-1 family and the complement subcomponents, C1r/C1s. These proteins contain both CUB and protease domains, and complex formation through the ligand binding domain is essential for their function. Activation of the serine protease domains of C1r and C1s requires
15 proteolytic cleavage of Arg-Gly and Arg-Ile bonds, respectively.¹⁵ Similarly, it might be expected that the TADG-15 protein is synthesized as a zymogen, which is activated by cleavage between Arg⁶¹⁴ and Val⁶¹⁵ and analogous to the activation mechanism of other serine protease zymogens. Western blot analysis of
20 cultured cell lysates confirmed both a 100 kDa and 32 kDa peptide, which correspond to the putative zymogen (whole molecule) and a cleaved protease product of TADG-15 (Figure 9). These data support a model for proteolytic release and/or activation of TADG-15 as occurs for similar type II serine
25 proteases.

CUB domains were first found in complement subcomponents C1r/C1s¹⁶⁻¹⁸ and are known to be a widespread module in developmentally regulated proteins, such as the bone morphogenetic protein-1 (BMP-1) and the tolloid gene product.¹⁸⁻

²⁰ The role of these repeats remains largely unknown. However, some models suggest that the CUB domain may be involved in protein-protein interactions. The CUB domain of Clr and Cls participates in the assembly of the Cls-Clr-Clr-Cl_s tetrameric
5 complex in the activation of the classical pathway of complement by providing protein-protein interaction domains.¹⁵ The *Drosophila* decapentaplegic (DPP) protein is essential for dorsal-ventral specification of the embryo, and the *Drosophila* tolloid (TLD) forms a complex with DPP to regulate its activity.^{19,20}
10 Missense mutations in the CUB domain of the tolloid protein results in a phenotype that does not allow a protein interaction with the DPP complex.¹⁹

The TADG-15 protein contains two tandem repeats of CUB-like domains between amino acid residues 214 and 447.
15 Each of these is approximately 110 amino acids long and each has four conserved cysteine residues characteristic of other CUBs (amino acids 214, 244, 268, 294, 340, 366, 397, 410). By analogy, the CUB repeats of the TADG-15 protein may form an interactive domain capable of promoting multimeric complex
20 formation and regulating the activity of the target protein or TADG-15 itself.

The TADG-15 protein also contains the LDL receptor ligand binding repeat (class A motif) -like domain, which consists of four contiguous cysteine-rich repeats (amino acid residues 453
25 to 602). Each cysteine-rich repeat is approximately 40 amino acids long and contains a conserved, negatively-charged sequence (Ser-Asp-Glu) with six cysteine residues. In the LDL receptor protein, this repeat is thought to function as a protein-binding domain which interacts with the lysine and arginine residues

present in lipoproteins.^{21,22} In addition, the first repeat of the LDL receptor appears to bind Ca^{2+} and not the lipoproteins.²³ By analogy, it is possible that the LDL receptor-like repeat in TADG-15 may act in a similar fashion, interacting with positively charged regions of other proteins and/or as a Ca^{2+} binding site. As a result of ligand binding and the formation of receptor-ligand complex, LDL receptor is internalized via clathrin-coated pits.²⁴ These types of plasma membrane receptors contain a characteristic amino acid sequence in their cytoplasmic domain for binding to clathrin-coated pits.²⁴ TADG-15 does not contain this motif in its cytosolic region, and furthermore, no similarities with other known protein sequences were found in the cytoplasmic domain of the TADG-15. This finding suggests that TADG-15 functions in a different manner from the endocytic receptors (such as the LDL receptor), although TADG-15 possesses similar ligand-binding repeats in the extracellular matrix.

Although the precise role of TADG-15 is unknown, this gene is clearly overexpressed in ovarian tumors. A variety of proteases, such as type IV collagenase and plasminogen activator, appear to be involved in the process of tumor invasion and are constituents of a protease cascade in malignant progression. TADG-15 may constitute such an activity and directly digest extracellular matrix components surrounding a tumor, or activate other proteases by cleavage of inactive precursors, indirectly enhancing tumor growth and invasion. It is also possible that TADG-15 may function like a member of the tolloid/BMP-1 family by forming complexes with other growth factors or signal transduction proteins to modulate their activities.

These data raise the possibility that the TADG-15 gene and its translated protein will be a useful marker for the early detection of ovarian carcinoma through release of the protease domain into the extracellular matrix and ultimately the circulation. These data also suggest the possibility of using TADG-15 as a target for therapeutic intervention through delivery systems directed at the CUB/LDLR ligand binding domains.

The following references were cited herein:

1. Liotta, L.A., et al. *Cell*, 64: 327-336, 1991.
- 10 2. Duffy, M.J. *Clin. Exp. Metastasis*, 10: 145-155, 1992.
3. Tryggvason, K., et al. *Biochem. Biophys. Acta.*, 907: 191-217, 1987.
4. Levy, A.T., et al. *Cancer Res.*, 51: 439-444, 1991.
5. Monsky, W.L. et al. *Cancer Res.*, 53: 3159-3164, 1993.
- 15 6. Duffy, M.J. et al. *Cancer*, 62: 531-533, 1988.
7. Häckel, C., et al. *Cancer*, 79: 53-58, 1997.
8. Watt, et al. *Proc.Natl. Acad. Sci.U.S.A.*, 83:3166-3170, 1986.
9. Tanimoto, H. et al. *Cancer Res.*, 57: 2884-2887, 1997.
11. Shigemasa, K. et al. *J. Soc. Gynecol. Invest.*, 4: 95-102, 20 1997.
12. Tanimoto, H. et al. *Gynecol. Oncol.*, 66: 308-312, 1997.
13. Maniatis, T., Fritsch, E.F. & Sambrook, J. *Molecular Cloning*, p. 309-361 Cold Spring Harbor Laboratory, New York, 1982.
14. Kim, M.G., et al. *Immunogenetics*, 49(5): 420-428, 1999.
- 25 15. Arlaud et al. *Method in Enzymology*, 223: 61-82, 1993.
16. Journet, A. & Tosi, M. *Biochem. J.*, 240: 783-787, 1986.
17. Mackinnon, et al. *Eur. J. Biochem.*, 169: 547-553, 1987.
18. Bork, P. & Beckmann, G. *J. Mol. Biol.*, 231: 539-545, 1993.
19. Childs, & O'Connor, M.B. *Dev. Biol.*, 162: 209-220, 1994.

20. Blader, PL, et al. Science, 278: 1937-1940, 1997.
21. Yamamoto, T. et al. Cell, 39: 27-38, 1984.
22. Daly, N.L., et al. Proc. Natl. Acad. Sci., 92: 6334-6338, 1995.
23. van Driel, I.R., et al. J. Biol. Chem., 262: 17443-17449,
5 1987.
24. Lodish, H. et al. Sorting of membrane proteins internalized from the cell surface. *In: Molecular Cell Biology*, 3rd ed., p.722-733 Scientific American Books, Inc., New York, 1995.
25. Parker, KC et al. J. Immunol. 152:163, 1994.

10 Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains.

15

 One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The present examples along with the methods,
20 procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed
25 within the spirit of the invention as defined by the scope of the claims.

SEQUENCE LISTING

<110> The Board of Trustees of the University of Arkansas

<120> TADG-15: An Extracellular Serine Protease
Overexpressed in Carcinomas

<130> PAT 52243W-1

<140> 2,388,450

<141> 2000-10-20

<150> 09/421,213

<151> 1999-10-20

<160> 98

<210> 1

<211> 3147

<212> DNA

<213> Homo sapiens

<220>

<223> TADG-15

<400> 1

```

tcaagagcgg cctcggggta ccatggggag cgatcgggcc cgcaagggcg 50
gagggggccc gaaggacttc ggcgcgggac tcaagtacaa ctcccggcac 100
gagaaagtga atggccttga ggaaggcgtg gagttcctgc cagtcaacaa 150
cgtcaagaag gtggaaaagc atggcccggg gcgctgggtg gtgctggcag 200
ccgtgctgat cggcctcctc ttggtccttc tggggatcgg cttcctgggtg 250
tggcatttgc agtaccggga cgtgcgtgtc cagaagggtc tcaatggcta 300
catgaggatc acaaatgaga attttgtgga tgcctacgag aactccaact 350
ccactgagtt tgtaagcctg gccagcaagg tgaaggacgc gctgaagctg 400
ctgtacagcg gagtcccatt cctgggcccc taccacaagg agtcggctgt 450
gacggccttc agcgagggca gcgtcatcgc ctactactgg tctgagttca 500
gcatcccgca gcacctgggtg gaggaggccg agcgcgtcat ggccgaggag 550
cgcgtagtca tgctgcccc cggggcgcg cccctgaagt cctttgtggt 600
cacctcagtg gtggctttcc ccacggactc caaaacagta cagaggacc 650
aggacaacag ctgcagcttt ggctgcacg cccgcggtgt ggagctgatg 700
cgcttcacca cgcccggctt cctgacagc ccctaccccg ctcagtcgg 750
ctgccagtg gcccgcggg gggacgccga ctcagtgctg agcctcacct 800
tccgcagctt tgaccttgcg tctgcgacg agcgcggcag cgacctgggtg 850
acgggtgtaca acaccttgag ccccatggag cccacgccc tgggtgcagtt 900
gtgtggcacc taccctccct cctacaacct gaccttccac tctcccaga 950
acgtcctgct catcacactg ataaccaaca ctgagcggcg gcatcccggc 1000
tttgaggcca ctttcttcca gctgcctagg atgagcagct gtggaggccg 1050
cttacgtaaa gccagggga cattcaacag ccctactac ccaggccact 1100
accacccaa cattgactgc acatggaaca ttgaggtgcc caacaaccag 1150
catgtgaagg tgagcttcaa attcttctac ctgctggagc ccggcgtgcc 1200
tgcgggcacc tgcccaagg actacgtgga gatcaatggg gagaaatact 1250
gcggagagag gtcccagttc gtcgtcacca gcaacagcaa caagatcaca 1300

```

```

gttcgcttcc actcagatca gtcctacacc gacacgggt tcttagctga 1350
atacctctcc tacgactcca gtgacccatg cccggggcag ttcacgtgcc 1400
gcacggggcg gtgtatccgg aaggagctgc gctgtgatgg ctgggccgac 1450
tgcaccgacc acagcgatga gctcaactgc agttgcgacg ccggccacca 1500
gttcacgtgc aagaacaagt tctgcaagcc cctcttctgg gtctgcgaca 1550
gtgtgaacga ctgcggagac aacagcgacg agcaggggtg cagttgtccg 1600
gcccagacct tcaggtgttc caatgggaag tgcctctcga aaagccagca 1650
gtgcaatggg aaggacgact gtggggacgg gtccgacgag gcctcctgcc 1700
ccaaggtgaa cgtcgtcact tgtaccaaac acacctaccg ctgcctcaat 1750
gggctctgct tgagcaaggg caaccctgag tgtgacggga aggaggactg 1800
tagcgacggc tcagatgaga aggactgcga ctgtgggctg cggtcattca 1850
cgagacaggc tcgtgttgtt gggggcacgg atgcggatga gggcgagtgg 1900
ccctggcagg taagcctgca tgctctgggc cagggccaca tctgcggtgc 1950
ttccctcatc tctcccaact ggctggtctc tgccgcacac tgctacatcg 2000
atgacagagg attcaggtac tcagaccca cgcagtggac ggccttcttg 2050
ggcttgcacg accagagcca ggcgacgcc cctgggggtg aggagcgcag 2100
gctcaagcgc atcatctccc accccttctt caatgacttc accttcgact 2150
atgacatcgc gctgctggag ctggagaaac cggcagagta cagctccatg 2200
gtgcggccca tctgcctgcc ggacgcctcc catgtcttcc ctgccggcaa 2250
ggccatctgg gtcacgggct ggggacacac ccagtatgga ggcactggcg 2300
cgctgatcct gcaaaagggg gagatccgcg tcatcaacca gaccacctgc 2350
gagaacctcc tgccgcagca gatcacgccg cgcagtatgt gcgtgggctt 2400
cctcagcggc ggcgtggact cctgccaggg tgattccggg ggacctctgt 2450
ccagcgtgga ggcggatggg cggatcttcc aggccgggtg ggtgagctgg 2500
ggagacggct gcgctcagag gaacaagcca ggcgtgtaca caaggctccc 2550
tctgtttcgg gactggatca aagagaacac tggggatatag gggccggggc 2600
cacccaaatg tgtacacctg cggggccacc catcgtccac ccagtggtgc 2650
acgcctgcag gctggagact ggaccgctga ctgcaccagc gccccagaa 2700
catacactgt gaactcaatc tccagggtc caaatctgcc tagaaaacct 2750
ctcgcttctt cagcctccaa agtggagctg ggaggtagaa ggggaggaca 2800
ctgggtggtt tactgacca actgggggca aaggtttgaa gacacagcct 2850
cccccgccag ccccaagctg ggccgaggcg cgtttgtgta tatctgcctc 2900
ccctgtctgt aaggagcagc gggaacggag cttcggagcc tctcagtga 2950
aggtgggtgg gctgccggat ctgggctgtg gggcccttgg gccacgctct 3000
tgaggaagcc caggctcgga ggaccctgga aaacagacgg gtctgagact 3050
gaaattgttt taccagctcc caggggtggac ttcagtggtg gtatttgtgt 3100
aaatgggtaa aacaatttat ttctttttaa aaaaaaaaaa aaaaaaa 3147

```

```

<210> 2
<211> 855
<212> PRT
<213> Homo sapiens

```

```

<220>
<223> TADG-15

```

```

<400> 2

```

```

Met Gly Ser Asp Arg Ala Arg Lys Gly Gly Gly Gly Pro Lys Asp
      5                      10                      15
Phe Gly Ala Gly Leu Lys Tyr Asn Ser Arg His Glu Lys Val Asn
      20                      25                      30

```

Gly	Leu	Glu	Glu	Gly	Val	Glu	Phe	Leu	Pro	Val	Asn	Asn	Val	Lys	35	40	45
Lys	Val	Glu	Lys	His	Gly	Pro	Gly	Arg	Trp	Val	Val	Leu	Ala	Ala	50	55	60
Val	Leu	Ile	Gly	Leu	Leu	Leu	Val	Leu	Leu	Gly	Ile	Gly	Phe	Leu	65	70	75
Val	Trp	His	Leu	Gln	Tyr	Arg	Asp	Val	Arg	Val	Gln	Lys	Val	Phe	80	85	90
Asn	Gly	Tyr	Met	Arg	Ile	Thr	Asn	Glu	Asn	Phe	Val	Asp	Ala	Tyr	95	100	105
Glu	Asn	Ser	Asn	Ser	Thr	Glu	Phe	Val	Ser	Leu	Ala	Ser	Lys	Val	110	115	120
Lys	Asp	Ala	Leu	Lys	Leu	Leu	Tyr	Ser	Gly	Val	Pro	Phe	Leu	Gly	125	130	135
Pro	Tyr	His	Lys	Glu	Ser	Ala	Val	Thr	Ala	Phe	Ser	Glu	Gly	Ser	140	145	150
Val	Ile	Ala	Tyr	Tyr	Trp	Ser	Glu	Phe	Ser	Ile	Pro	Gln	His	Leu	155	160	165
Val	Glu	Glu	Ala	Glu	Arg	Val	Met	Ala	Glu	Glu	Arg	Val	Val	Met	170	175	180
Leu	Pro	Pro	Arg	Ala	Arg	Ser	Leu	Lys	Ser	Phe	Val	Val	Thr	Ser	185	190	195
Val	Val	Ala	Phe	Pro	Thr	Asp	Ser	Lys	Thr	Val	Gln	Arg	Thr	Gln	200	205	210
Asp	Asn	Ser	Cys	Ser	Phe	Gly	Leu	His	Ala	Arg	Gly	Val	Glu	Leu	215	220	225
Met	Arg	Phe	Thr	Thr	Pro	Gly	Phe	Pro	Asp	Ser	Pro	Tyr	Pro	Ala	230	235	240
His	Ala	Arg	Cys	Gln	Trp	Ala	Leu	Arg	Gly	Asp	Ala	Asp	Ser	Val	245	250	255
Leu	Ser	Leu	Thr	Phe	Arg	Ser	Phe	Asp	Leu	Ala	Ser	Cys	Asp	Glu	260	265	270
Arg	Gly	Ser	Asp	Leu	Val	Thr	Val	Tyr	Asn	Thr	Leu	Ser	Pro	Met	275	280	285
Glu	Pro	His	Ala	Leu	Val	Gln	Leu	Cys	Gly	Thr	Tyr	Pro	Pro	Ser	290	295	300
Tyr	Asn	Leu	Thr	Phe	His	Ser	Ser	Gln	Asn	Val	Leu	Leu	Ile	Thr	305	310	315
Leu	Ile	Thr	Asn	Thr	Glu	Arg	Arg	His	Pro	Gly	Phe	Glu	Ala	Thr	320	325	330
Phe	Phe	Gln	Leu	Pro	Arg	Met	Ser	Ser	Cys	Gly	Gly	Arg	Leu	Arg	335	340	345
Lys	Ala	Gln	Gly	Thr	Phe	Asn	Ser	Pro	Tyr	Tyr	Pro	Gly	His	Tyr	350	355	360
Pro	Pro	Asn	Ile	Asp	Cys	Thr	Trp	Asn	Ile	Glu	Val	Pro	Asn	Asn	365	370	375
Gln	His	Val	Lys	Val	Ser	Phe	Lys	Phe	Phe	Tyr	Leu	Leu	Glu	Pro	380	385	390
Gly	Val	Pro	Ala	Gly	Thr	Cys	Pro	Lys	Asp	Tyr	Val	Glu	Ile	Asn	395	400	405
Gly	Glu	Lys	Tyr	Cys	Gly	Glu	Arg	Ser	Gln	Phe	Val	Val	Thr	Ser	410	415	420
Asn	Ser	Asn	Lys	Ile	Thr	Val	Arg	Phe	His	Ser	Asp	Gln	Ser	Tyr	425	430	435

Thr	Asp	Thr	Gly	Phe	Leu	Ala	Glu	Tyr	Leu	Ser	Tyr	Asp	Ser	Ser
				440					445					450
Asp	Pro	Cys	Pro	Gly	Gln	Phe	Thr	Cys	Arg	Thr	Gly	Arg	Cys	Ile
				455					460					465
Arg	Lys	Glu	Leu	Arg	Cys	Asp	Gly	Trp	Ala	Asp	Cys	Thr	Asp	His
				470					475					480
Ser	Asp	Glu	Leu	Asn	Cys	Ser	Cys	Asp	Ala	Gly	His	Gln	Phe	Thr
				485					490					495
Cys	Lys	Asn	Lys	Phe	Cys	Lys	Pro	Leu	Phe	Trp	Val	Cys	Asp	Ser
				500					505					510
Val	Asn	Asp	Cys	Gly	Asp	Asn	Ser	Asp	Glu	Gln	Gly	Cys	Ser	Cys
				515					520					525
Pro	Ala	Gln	Thr	Phe	Arg	Cys	Ser	Asn	Gly	Lys	Cys	Leu	Ser	Lys
				530					535					540
Ser	Gln	Gln	Cys	Asn	Gly	Lys	Asp	Asp	Cys	Gly	Asp	Gly	Ser	Asp
				545					550					555
Glu	Ala	Ser	Cys	Pro	Lys	Val	Asn	Val	Val	Thr	Cys	Thr	Lys	His
				560					565					570
Thr	Tyr	Arg	Cys	Leu	Asn	Gly	Leu	Cys	Leu	Ser	Lys	Gly	Asn	Pro
				575					580					585
Glu	Cys	Asp	Gly	Lys	Glu	Asp	Cys	Ser	Asp	Gly	Ser	Asp	Glu	Lys
				590					595					600
Asp	Cys	Asp	Cys	Gly	Leu	Arg	Ser	Phe	Thr	Arg	Gln	Ala	Arg	Val
				605					610					615
Val	Gly	Gly	Thr	Asp	Ala	Asp	Glu	Gly	Glu	Trp	Pro	Trp	Gln	Val
				620					625					630
Ser	Leu	His	Ala	Leu	Gly	Gln	Gly	His	Ile	Cys	Gly	Ala	Ser	Leu
				635					640					645
Ile	Ser	Pro	Asn	Trp	Leu	Val	Ser	Ala	Ala	His	Cys	Tyr	Ile	Asp
				650					655					660
Asp	Arg	Gly	Phe	Arg	Tyr	Ser	Asp	Pro	Thr	Gln	Trp	Thr	Ala	Phe
				665					670					675
Leu	Gly	Leu	His	Asp	Gln	Ser	Gln	Arg	Ser	Ala	Pro	Gly	Val	Gln
				680					685					690
Glu	Arg	Arg	Leu	Lys	Arg	Ile	Ile	Ser	His	Pro	Phe	Phe	Asn	Asp
				695					700					705
Phe	Thr	Phe	Asp	Tyr	Asp	Ile	Ala	Leu	Leu	Glu	Leu	Glu	Lys	Pro
				710					715					720
Ala	Glu	Tyr	Ser	Ser	Met	Val	Arg	Pro	Ile	Cys	Leu	Pro	Asp	Ala
				725					730					735
Ser	His	Val	Phe	Pro	Ala	Gly	Lys	Ala	Ile	Trp	Val	Thr	Gly	Trp
				740					745					750
Gly	His	Thr	Gln	Tyr	Gly	Gly	Thr	Gly	Ala	Leu	Ile	Leu	Gln	Lys
				755					760					765
Gly	Glu	Ile	Arg	Val	Ile	Asn	Gln	Thr	Thr	Cys	Glu	Asn	Leu	Leu
				770					775					780
Pro	Gln	Gln	Ile	Thr	Pro	Arg	Met	Met	Cys	Val	Gly	Phe	Leu	Ser
				785					790					795
Gly	Gly	Val	Asp	Ser	Cys	Gln	Gly	Asp	Ser	Gly	Gly	Pro	Leu	Ser
				800					805					810
Ser	Val	Glu	Ala	Asp	Gly	Arg	Ile	Phe	Gln	Ala	Gly	Val	Val	Ser
				815					820					825
Trp	Gly	Asp	Gly	Cys	Ala	Gln	Arg	Asn	Lys	Pro	Gly	Val	Tyr	Thr
				830					835					840

Arg Leu Pro Leu Phe Arg Asp Trp Ile Lys Glu Asn Thr Gly Val
845 850 855

```
<210>      3
<211>      256
<212>      PRT
<213>      Homo sapiens
```

<220>
<223> Hepsin

<400> 3

[illegible]

<210>	4
<211>	225
<212>	PRT

<213> Homo sapiens

<220>

<223> SCCE

<400> 4

Lys	Ile	Ile	Asp	Gly	Ala	Pro	Cys	Ala	Arg	Gly	Ser	His	Pro	Trp	
				5					10					15	
Gln	Val	Ala	Leu	Leu	Ser	Gly	Asn	Gln	Leu	His	Cys	Gly	Gly	Val	
				20					25					30	
Leu	Val	Asn	Glu	Arg	Trp	Val	Leu	Thr	Ala	Ala	His	Cys	Lys	Met	
				35					40					45	
Asn	Glu	Tyr	Thr	Val	His	Leu	Gly	Ser	Asp	Thr	Leu	Gly	Asp	Arg	
				50					55					60	
Arg	Ala	Gln	Arg	Ile	Lys	Ala	Ser	Lys	Ser	Phe	Arg	His	Pro	Gly	
				65					70					75	
Tyr	Ser	Thr	Gln	Thr	His	Val	Asn	Asp	Leu	Met	Leu	Val	Lys	Leu	
				80					85					90	
Asn	Ser	Gln	Ala	Arg	Leu	Ser	Ser	Met	Val	Lys	Lys	Val	Arg	Leu	
				95					100					105	
Pro	Ser	Arg	Cys	Glu	Pro	Pro	Gly	Thr	Thr	Cys	Thr	Val	Ser	Gly	
				110					115					120	
Trp	Gly	Thr	Thr	Thr	Ser	Pro	Asp	Val	Thr	Phe	Pro	Ser	Asp	Leu	
				125					130					135	
Met	Cys	Val	Asp	Val	Lys	Leu	Ile	Ser	Pro	Gln	Asp	Cys	Thr	Lys	
				140					145					150	
Val	Tyr	Lys	Asp	Leu	Leu	Glu	Asn	Ser	Met	Leu	Cys	Ala	Gly	Ile	
				155					160					165	
Pro	Asp	Ser	Lys	Lys	Asn	Ala	Cys	Asn	Gly	Asp	Ser	Gly	Gly	Pro	
				170					175					180	
Leu	Val	Cys	Arg	Gly	Thr	Leu	Gln	Gly	Leu	Val	Ser	Trp	Gly	Thr	
				185					190					195	
Phe	Pro	Cys	Gly	Gln	Pro	Asn	Asp	Pro	Gly	Val	Tyr	Thr	Gln	Val	
				200					205					210	
Cys	Lys	Phe	Thr	Lys	Trp	Ile	Asn	Asp	Thr	Met	Lys	Lys	His	Arg	
				215					220					225	

<210> 5

<211> 225

<212> PRT

<213> Homo sapiens

<220>

<223> Trypsin

<400> 5

Lys	Ile	Val	Gly	Gly	Tyr	Asn	Cys	Glu	Glu	Asn	Ser	Val	Pro	Tyr	
				5					10					15	
Gln	Val	Ser	Leu	Asn	Ser	Gly	Tyr	His	Phe	Cys	Gly	Gly	Ser	Leu	
				20					25					30	

Ile	Asn	Glu	Gln	Trp	Val	Val	Ser	Ala	Gly	His	Cys	Tyr	Lys	Ser
				35					40					45
Arg	Ile	Gln	Val	Arg	Leu	Gly	Glu	His	Asn	Ile	Glu	Val	Leu	Glu
				50					55					60
Gly	Asn	Glu	Gln	Phe	Ile	Asn	Ala	Ala	Lys	Ile	Ile	Arg	His	Pro
				65					70					75
Gln	Tyr	Asp	Arg	Lys	Thr	Leu	Asn	Asn	Asp	Ile	Met	Leu	Ile	Lys
				80					85					90
Leu	Ser	Ser	Arg	Ala	Val	Ile	Asn	Ala	Arg	Val	Ser	Thr	Ile	Ser
				95					100					105
Leu	Pro	Thr	Ala	Pro	Pro	Ala	Thr	Gly	Thr	Lys	Cys	Leu	Ile	Ser
				110					115					120
Gly	Trp	Gly	Asn	Thr	Ala	Ser	Ser	Gly	Ala	Asp	Tyr	Pro	Asp	Glu
				125					130					135
Leu	Gln	Cys	Leu	Asp	Ala	Pro	Val	Leu	Ser	Gln	Ala	Lys	Cys	Glu
				140					145					150
Ala	Ser	Tyr	Pro	Gly	Lys	Ile	Thr	Ser	Asn	Met	Phe	Cys	Val	Gly
				155					160					165
Phe	Leu	Glu	Gly	Gly	Lys	Asp	Ser	Cys	Gln	Gly	Asp	Ser	Gly	Gly
				170					175					180
Pro	Val	Val	Cys	Asn	Gly	Gln	Leu	Gln	Gly	Val	Val	Ser	Trp	Gly
				185					190					195
Asp	Gly	Cys	Ala	Gln	Lys	Asn	Lys	Pro	Gly	Val	Tyr	Thr	Lys	Val
				200					205					210
Tyr	Asn	Tyr	Val	Lys	Trp	Ile	Lys	Asn	Thr	Ile	Ala	Ala	Asn	Ser
				215					220					225

<210> 6
 <211> 231
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Chymotrypsin

<400> 6

Arg	Ile	Val	Asn	Gly	Glu	Asp	Ala	Val	Pro	Gly	Ser	Trp	Pro	Trp
				5					10					15
Gln	Val	Ser	Leu	Gln	Asp	Lys	Thr	Gly	Phe	His	Phe	Cys	Gly	Gly
				20					25					30
Ser	Leu	Ile	Ser	Glu	Asp	Trp	Val	Val	Thr	Ala	Ala	His	Cys	Gly
				35					40					45
Val	Arg	Thr	Ser	Asp	Val	Val	Val	Ala	Gly	Glu	Phe	Asp	Gln	Gly
				50					55					60
Ser	Asp	Glu	Glu	Asn	Ile	Gln	Val	Leu	Lys	Ile	Ala	Lys	Val	Phe
				65					70					75
Lys	Asn	Pro	Lys	Phe	Ser	Ile	Leu	Thr	Val	Asn	Asn	Asp	Ile	Thr
				80					85					90
Leu	Leu	Lys	Leu	Ala	Thr	Pro	Ala	Arg	Phe	Ser	Gln	Thr	Val	Ser
				95					100					105
Ala	Val	Cys	Leu	Pro	Ser	Ala	Asp	Asp	Asp	Phe	Pro	Ala	Gly	Thr
				110					115					120

Leu	Cys	Ala	Thr	Thr	Gly	Trp	Gly	Lys	Thr	Lys	Tyr	Asn	Ala	Asn
				125					130					135
Lys	Thr	Pro	Asp	Lys	Leu	Gln	Gln	Ala	Ala	Leu	Pro	Leu	Leu	Ser
				140					145					150
Asn	Ala	Glu	Cys	Lys	Lys	Ser	Trp	Gly	Arg	Arg	Ile	Thr	Asp	Val
				155					160					165
Met	Ile	Cys	Ala	Gly	Ala	Ser	Gly	Val	Ser	Ser	Cys	Met	Gly	Asp
				170					175					180
Ser	Gly	Gly	Pro	Leu	Val	Cys	Gln	Lys	Asp	Gly	Ala	Trp	Thr	Leu
				185					190					195
Val	Gly	Ile	Val	Ser	Trp	Gly	Ser	Asp	Thr	Cys	Ser	Thr	Ser	Ser
				200					205					210
Pro	Gly	Val	Tyr	Ala	Arg	Val	Thr	Lys	Leu	Ile	Pro	Trp	Val	Gln
				215					220					225
Lys	Ile	Leu	Ala	Ala	Asn									
				230										

<210> 7
 <211> 255
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Factor 7

<400> 7

Arg	Ile	Val	Gly	Gly	Lys	Val	Cys	Pro	Lys	Gly	Glu	Cys	Pro	Trp
				5					10					15
Gln	Val	Leu	Leu	Leu	Val	Asn	Gly	Ala	Gln	Leu	Cys	Gly	Gly	Thr
				20					25					30
Leu	Ile	Asn	Thr	Ile	Trp	Val	Val	Ser	Ala	Ala	His	Cys	Phe	Asp
				35					40					45
Lys	Ile	Lys	Asn	Trp	Arg	Asn	Leu	Ile	Ala	Val	Leu	Gly	Glu	His
				50					55					60
Asp	Leu	Ser	Glu	His	Asp	Gly	Asp	Glu	Gln	Ser	Arg	Arg	Val	Ala
				65					70					75
Gln	Val	Ile	Ile	Pro	Ser	Thr	Tyr	Val	Pro	Gly	Thr	Thr	Asn	His
				80					85					90
Asp	Ile	Ala	Leu	Leu	Arg	Leu	His	Gln	Pro	Val	Val	Leu	Thr	Asp
				95					100					105
His	Val	Val	Pro	Leu	Cys	Leu	Pro	Glu	Arg	Thr	Phe	Ser	Glu	Arg
				110					115					120
Thr	Leu	Ala	Phe	Val	Arg	Phe	Ser	Leu	Val	Ser	Gly	Trp	Gly	Gln
				125					130					135
Leu	Leu	Asp	Arg	Gly	Ala	Thr	Ala	Leu	Glu	Leu	Met	Val	Leu	Asn
				140					145					150
Val	Pro	Arg	Leu	Met	Thr	Gln	Asp	Cys	Leu	Gln	Gln	Ser	Arg	Lys
				155					160					165
Val	Gly	Asp	Ser	Pro	Asn	Ile	Thr	Glu	Tyr	Met	Phe	Cys	Ala	Gly
				170					175					180
Tyr	Ser	Asp	Gly	Ser	Lys	Asp	Ser	Cys	Lys	Gly	Asp	Ser	Gly	Gly
				185					190					195

Pro	His	Ala	Thr	His	Tyr	Arg	Gly	Thr	Trp	Tyr	Leu	Thr	Gly	Ile
				200					205					210
Val	Ser	Trp	Gly	Gln	Gly	Cys	Ala	Thr	Val	Gly	His	Phe	Gly	Val
				215					220					225
Tyr	Thr	Arg	Val	Ser	Gln	Tyr	Ile	Glu	Trp	Leu	Gln	Lys	Leu	Met
				230					235					240
Arg	Ser	Glu	Pro	Arg	Pro	Gly	Val	Leu	Leu	Arg	Ala	Pro	Phe	Pro
				245					250					255

<210> 8
 <211> 253
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Tissue plasminogen activator

<400> 8

Arg	Ile	Lys	Gly	Gly	Leu	Phe	Ala	Asp	Ile	Ala	Ser	His	Pro	Trp
				5					10					15
Gln	Ala	Ala	Ile	Phe	Ala	Lys	His	Arg	Arg	Ser	Pro	Gly	Glu	Arg
				20					25					30
Phe	Leu	Cys	Gly	Gly	Ile	Leu	Ile	Ser	Ser	Cys	Trp	Ile	Leu	Ser
				35					40					45
Ala	Ala	His	Cys	Phe	Gln	Glu	Arg	Phe	Pro	Pro	His	His	Leu	Thr
				50					55					60
Val	Ile	Leu	Gly	Arg	Thr	Tyr	Arg	Val	Val	Pro	Gly	Glu	Glu	Glu
				65					70					75
Gln	Lys	Phe	Glu	Val	Glu	Lys	Tyr	Ile	Val	His	Lys	Glu	Phe	Asp
				80					85					90
Asp	Asp	Thr	Tyr	Asp	Asn	Asp	Ile	Ala	Leu	Leu	Gln	Leu	Lys	Ser
				95					100					105
Asp	Ser	Ser	Arg	Cys	Ala	Gln	Glu	Ser	Ser	Val	Val	Arg	Thr	Val
				110					115					120
Cys	Leu	Pro	Pro	Ala	Asp	Leu	Gln	Leu	Pro	Asp	Trp	Thr	Glu	Cys
				125					130					135
Glu	Leu	Ser	Gly	Tyr	Gly	Lys	His	Glu	Ala	Leu	Ser	Pro	Phe	Tyr
				140					145					150
Ser	Glu	Arg	Leu	Lys	Glu	Ala	His	Val	Arg	Leu	Tyr	Pro	Ser	Ser
				155					160					165
Arg	Cys	Thr	Ser	Gln	His	Leu	Leu	Asn	Arg	Thr	Val	Thr	Asp	Asn
				170					175					180
Met	Leu	Cys	Ala	Gly	Asp	Thr	Arg	Ser	Gly	Gly	Pro	Gln	Ala	Asn
				185					190					195
Leu	His	Asp	Ala	Cys	Gln	Gly	Asp	Ser	Gly	Gly	Pro	Leu	Val	Cys
				200					205					210
Leu	Asn	Asp	Gly	Arg	Met	Thr	Leu	Val	Gly	Ile	Ile	Ser	Trp	Gly
				215					220					225
Leu	Gly	Cys	Gly	Gln	Lys	Asp	Val	Pro	Gly	Val	Tyr	Thr	Lys	Val
				230					235					240
Thr	Asn	Tyr	Leu	Asp	Trp	Ile	Arg	Asp	Asn	Met	Arg	Pro		
				245					250					

<210> 9
 <211> 2900
 <212> DNA
 <213> Homo sapiens

<220>
 <223> SNC-19; GeneBank Accession No. #U20428

<400> 9

```

cgctgggtgg tgctggcagc cgtgctgac gccctcctct tggctcttgc 50
ggggatcggc ttcctgggtgt ggcatattgca gtaccgggac gtgcgtgtcc 100
agaaggtcct caatggctac atgaggatca caaatgagaa ttttgtggat 150
gcctacgaga actccaactc cactgagttt gtaagcctgg ccagcaaggt 200
gaaggacgcg ctgaagctgc tgtacagcgg agtcccatte ctgggcccct 250
accacaagga gtcggctgtg acggccttca gcgagggcag cgtcatcgcc 300
tactactggt ctgagttcag catcccgag cacctggttg aggaggccga 350
gcgcgtcatg gccaggagcg cgtagtcatg ctgccccgc gggcgcgctc 400
cctgaagtc tttgtggtca cctcagtggg ggctttcccc acggactcca 450
aaacagtaca gaggaccag gacaacagct gcagcttttg cctgcacgcc 500
gcggtgtgga gctgatgcgc ttcaccacgc cggttccct gacagcccct 550
accccgctca tgcccgtgc cagtgggctg cggggacgcg acgcagtgt 600
gagctactcg agctgactcg cagcttgact gcgcctcgac gagcgcgga 650
gcgacctggt gacgtgtaca acacctgag ccccatggag cccacgcct 700
ggtgagtgtg tggcacctac ctcctcctc acaacctgac cttccactcc 750
ctcccacgaa cgtcctgctc atcacactga taaccaacac tgacgcggca 800
tcccggcttt gaggccacct tcttccagct gcctaggatg agcagctgtg 850
gaggccgctt acgtaaagcc caggggacat tcaacagccc ctactacca 900
ggccactacc caccacaacat tgactgcaca tggaaaattg aggtgcccaa 950
caaccagcat gtgaaggtgc gcttcaaatt cttctacctg ctggagcccg 1000
gcgtgcctgc gggcacctgc cccaaggact acgtggagat caatggggag 1050
aaatactgcg gagagaggtc ccagttcgtc gtcaccagca acagcaacaa 1100
gatcacagtt cgcttccact cagatcagtc ctacaccgac accggcttct 1150
tagctgaata cctctcctac gactccagtg acctatgccc ggggcagttc 1200
acgtgccgca cggggcggtg tatccggaag gagctgcgt gtgatggctg 1250
ggcgactgca ccgaccacag cgatgagctc aactgcagtt gcgacgccgg 1300
ccaccagttc acgtgcaaga gcaagttctg caagctcttc tgggtctgcg 1350
acagtgtgaa cgagtgcgga gacaacagcg acgagcaggg ttgcatttgt 1400
ccggaccag accttcagggt gttccaatgg gaagtgcctc tcgaaaagcc 1450
agcagtgcaa tgggaaggac gactgtgggg acgggtccga cgaggcctce 1500
tgccccaagg tgaacgtcgt cacttgtagc aaacacacct accgctgcct 1550
caatgggctc tgcttgagca agggcaacct tgagtgtgac gggaaggagg 1600
actgtagcga cggctcagat gagaaggact gcgactgtgg gctgcggtca 1650
ttcacgagac aggtctcgtg ttgtgggggc acggatgcgg atgagggcga 1700
gtggccctgg caggtaagcc tgcattgctc gggccagggc cacatctgcg 1750
gtgcttccct catctctccc aactggctgg tctctgcgc aactgctac 1800
atcgatgaca gaggattcag gtactcagac cccacgcagg acggccttcc 1850
tgggcttgca cgaccagagc cagcgcaggc cctgggggtg aggagcgcag 1900
gctcaagcgc atcatctccc acccttctt caatgacttc acctcgact 1950
atgacatcgc gctgctggag ctggagaaac cggcagagta cagctccatg 2000
gtgcggccca tctgctgcc ggacgcctgc catgtcttcc ctgccggcaa 2050
ggccatctgg gtcacgggct ggggacacac ccagtatgga ggcactggcg 2100
cgctgatect gcaaaagggt gagatccgcg tcatcaacca gaccacctgc 2150

```

gagaacctcc tgccgcagca gatcacgccg cgcattgatgt gcgtgggctt 2200
 cctcagcggc ggcgtggact cctgccaggg tgattccggg ggacccctgt 2250
 ccagcgtgga ggcggatggg cggatcttcc aggccggtgt ggtgagctgg 2300
 ggagacgctg cgctcagagg aacaagccag gcgtgtacac aaggctccct 2350
 ctgttttcggg aatggatcaa agagaacact ggggtatagg ggccggggcc 2400
 acccaaattgt gtacacctgc ggggccaccc atcgtccacc ccagtgtgca 2450
 cgcttgcagg ctggagactc gcgcaccgtg acctgcacca gcgccccaga 2500
 acataactg tgaactcatc tccaggctca aatctgctag aaaacctctc 2550
 gcttcctcag cctccaaagt ggagctggga gggtagaagg ggaggaacac 2600
 tgggtggttct actgacccaa ctggggcaag gtttgaagca cagctccggc 2650
 agcccaagtg ggcgaggacg cgtttgtgca tactgccctg ctctatacac 2700
 ggaagacctg gatctctagt gagtgtgact gccggatctg gctgtggtcc 2750
 ttggccacgc ttcttgagga agcccaggct cggaggaccc tggaaaacag 2800
 acgggtctga gactgaaaat ggtttaccag ctcccagggtg acttcagtgt 2850
 gtgtattgtg taaatgagta aaacatttta tttcttttta aaaaaaaaaa 2900

<210> 10
 <211> 902
 <212> PRT
 <213> Mus musculus

<220>
 <223> Epithin

<400> 10

Met	Gly	Ser	Asn	Arg	Gly	Arg	Lys	Ala	Gly	Gly	Gly	Ser	Gln	Asp	5	10	15
Phe	Gly	Ala	Gly	Leu	Lys	Tyr	Asp	Ser	Arg	Leu	Glu	Asn	Met	Asn	20	25	30
Gly	Phe	Glu	Glu	Gly	Val	Glu	Phe	Leu	Pro	Ala	Asn	Asn	Ala	Lys	35	40	45
Lys	Val	Glu	Lys	Arg	Gly	Pro	Arg	Arg	Trp	Val	Val	Leu	Val	Ala	50	55	60
Val	Leu	Phe	Ser	Phe	Leu	Leu	Leu	Ser	Leu	Met	Ala	Gly	Leu	Leu	65	70	75
Val	Trp	His	Phe	His	Tyr	Arg	Asn	Val	Arg	Val	Gln	Lys	Val	Phe	80	85	90
Asn	Gly	His	Leu	Arg	Ile	Thr	Asn	Glu	Ile	Phe	Leu	Asp	Ala	Tyr	95	100	105
Glu	Asn	Ser	Thr	Ser	Thr	Glu	Phe	Ile	Ser	Leu	Ala	Ser	Gln	Val	110	115	120
Lys	Glu	Ala	Leu	Lys	Leu	Leu	Tyr	Asn	Glu	Val	Pro	Val	Leu	Gly	125	130	135
Pro	Tyr	His	Lys	Lys	Ser	Ala	Val	Thr	Ala	Phe	Ser	Glu	Gly	Ser	140	145	150
Val	Ile	Ala	Tyr	Tyr	Trp	Ser	Glu	Phe	Ser	Ile	Pro	Pro	His	Leu	155	160	165
Ala	Glu	Glu	Val	Asp	Arg	Ala	Met	Ala	Val	Glu	Arg	Val	Val	Thr	170	175	180
Leu	Pro	Pro	Arg	Ala	Arg	Ala	Leu	Lys	Ser	Phe	Val	Leu	Thr	Ser	185	190	195

Val	Val	Ala	Phe	Pro	Ile	Asp	Pro	Arg	Met	Leu	Gln	Arg	Thr	Gln
				200					205					210
Asp	Asn	Ser	Cys	Ser	Phe	Ala	Leu	His	Ala	His	Gly	Ala	Ala	Val
				215					220					225
Thr	Arg	Phe	Thr	Thr	Pro	Gly	Phe	Pro	Asn	Ser	Pro	Tyr	Pro	Ala
				230					235					240
His	Ala	Arg	Cys	Gln	Trp	Val	Leu	Arg	Gly	Asp	Ala	Asp	Ser	Val
				245					250					255
Leu	Ser	Leu	Thr	Phe	Arg	Ser	Phe	Asp	Val	Ala	Pro	Cys	Asp	Glu
				260					265					270
His	Gly	Ser	Asp	Leu	Val	Thr	Val	Tyr	Asp	Ser	Leu	Ser	Pro	Met
				275					280					285
Glu	Pro	His	Ala	Val	Val	Arg	Leu	Cys	Gly	Thr	Phe	Ser	Pro	Ser
				290					295					300
Tyr	Asn	Leu	Thr	Phe	Leu	Ser	Ser	Gln	Asn	Val	Phe	Leu	Val	Thr
				305					310					315
Leu	Ile	Thr	Asn	Thr	Gly	Arg	Arg	His	Leu	Gly	Phe	Glu	Ala	Thr
				320					325					330
Phe	Phe	Gln	Leu	Pro	Lys	Met	Ser	Ser	Cys	Gly	Gly	Val	Leu	Ser
				335					340					345
Asp	Thr	Gln	Gly	Thr	Phe	Ser	Ser	Pro	Tyr	Tyr	Pro	Gly	His	Tyr
				350					355					360
Pro	Pro	Asn	Ile	Asn	Cys	Thr	Trp	Asn	Ile	Lys	Val	Pro	Asn	Asn
				365					370					375
Arg	Asn	Val	Lys	Val	Arg	Phe	Lys	Leu	Phe	Tyr	Leu	Val	Asp	Pro
				380					385					390
Asn	Val	Pro	Val	Gly	Ser	Cys	Thr	Lys	Asp	Tyr	Val	Glu	Ile	Asn
				395					400					405
Gly	Glu	Lys	Gly	Ser	Gly	Glu	Arg	Ser	Gln	Phe	Val	Val	Ser	Ser
				410					415					420
Asn	Ser	Ser	Lys	Ile	Thr	Val	His	Phe	His	Ser	Asp	His	Ser	Tyr
				425					430					435
Thr	Asp	Thr	Gly	Phe	Leu	Ala	Glu	Tyr	Leu	Ser	Tyr	Asp	Ser	Asn
				440					445					450
Asp	Pro	Cys	Pro	Gly	Met	Phe	Met	Cys	Lys	Thr	Gly	Arg	Cys	Ile
				455					460					465
Arg	Lys	Glu	Leu	Arg	Cys	Asp	Gly	Trp	Ala	Asp	Cys	Pro	Asp	Tyr
				470					475					480
Ser	Asp	Glu	Arg	Tyr	Cys	Arg	Cys	Asn	Ala	Thr	His	Gln	Phe	Thr
				485					490					495
Cys	Lys	Asn	Gln	Phe	Cys	Lys	Pro	Leu	Phe	Trp	Val	Cys	Asp	Ser
				500					505					510
Val	Asn	Asp	Cys	Gly	Asp	Gly	Ser	Asp	Glu	Glu	Gly	Cys	Ser	Cys
				515					520					525
Pro	Ala	Gly	Ser	Phe	Lys	Cys	Ser	Asn	Gly	Lys	Cys	Leu	Pro	Gln
				530					535					540
Ser	Gln	Lys	Cys	Asn	Gly	Lys	Asp	Asn	Cys	Gly	Asp	Gly	Ser	Asp
				545					550					555
Glu	Ala	Ser	Cys	Asp	Ser	Val	Asn	Val	Val	Ser	Cys	Thr	Lys	Tyr
				560					565					570
Thr	Tyr	Arg	Cys	Gln	Asn	Gly	Leu	Cys	Leu	Ser	Lys	Gly	Asn	Pro
				575					580					585
Glu	Cys	Asp	Gly	Lys	Thr	Asp	Cys	Ser	Asp	Gly	Ser	Asp	Glu	Lys
				590					595					600

Asn	Cys	Asp	Cys	Gly	Leu	Arg	Ser	Phe	Thr	Lys	Gln	Ala	Arg	Val
				605					610					615
Val	Gly	Gly	Thr	Asn	Ala	Asp	Glu	Gly	Glu	Trp	Pro	Trp	Gln	Val
				620					625					630
Ser	Leu	His	Ala	Leu	Gly	Gln	Gly	His	Leu	Cys	Gly	Ala	Ser	Leu
				635					640					645
Ile	Ser	Pro	Asp	Trp	Leu	Val	Ser	Ala	Ala	His	Cys	Phe	Gln	Asp
				650					655					660
Asp	Lys	Asn	Phe	Lys	Tyr	Ser	Asp	Tyr	Thr	Met	Trp	Thr	Ala	Phe
				665					670					675
Leu	Gly	Leu	Leu	Asp	Gln	Ser	Lys	Arg	Ser	Ala	Ser	Gly	Val	Gln
				680					685					690
Glu	Leu	Lys	Leu	Lys	Arg	Ile	Ile	Thr	His	Pro	Ser	Phe	Asn	Asp
				695					700					705
Phe	Thr	Phe	Asp	Tyr	Asp	Ile	Ala	Leu	Leu	Glu	Leu	Glu	Lys	Ser
				710					715					720
Val	Glu	Tyr	Ser	Thr	Val	Val	Arg	Pro	Ile	Cys	Leu	Pro	Asp	Ala
				725					730					735
Thr	His	Val	Phe	Pro	Ala	Gly	Lys	Ala	Ile	Trp	Val	Thr	Gly	Trp
				740					745					750
Gly	His	Thr	Lys	Glu	Gly	Gly	Thr	Gly	Ala	Leu	Ile	Leu	Gln	Lys
				755					760					765
Gly	Glu	Ile	Arg	Val	Ile	Asn	Gln	Thr	Thr	Cys	Glu	Asp	Leu	Met
				770					775					780
Pro	Gln	Gln	Ile	Thr	Pro	Arg	Met	Met	Cys	Val	Gly	Phe	Leu	Ser
				785					790					795
Gly	Gly	Val	Asp	Ser	Cys	Gln	Gly	Asp	Ser	Gly	Gly	Pro	Leu	Ser
				800					805					810
Ser	Ala	Glu	Lys	Asp	Gly	Arg	Met	Phe	Gln	Ala	Gly	Val	Val	Ser
				815					820					825
Trp	Gly	Glu	Gly	Cys	Ala	Gln	Arg	Asn	Lys	Pro	Gly	Val	Tyr	Thr
				830					835					840
Arg	Leu	Pro	Cys	Ser	Ser	Gly	Leu	Asp	Gln	Arg	Ala	His	Trp	Gly
				845					850					855
Ile	Ala	Ala	Trp	Thr	Asp	Ser	Arg	Pro	Gln	Thr	Pro	Thr	Gly	Met
				860					865					870
Pro	Asp	Met	His	Thr	Trp	Ile	Gln	Glu	Arg	Asn	Thr	Asp	Asp	Ile
				875					880					885
Tyr	Ala	Val	Ala	Ser	Pro	Pro	Gln	His	Asn	Pro	Asp	Cys	Glu	Leu
				890					895					900

His Pro

<210> 11

<211> 23

<212> DNA

<213> Artificial sequence

<220>

<221> n=Inosine

<222> 6, 9, 12, 15, 18

<223> Degenerate oligonucleotide primer

<400> 11

tgggtngtna cngcngcnca ytg 23

<210> 12
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <221> n=Inosine
 <222> 3, 6, 9, 12, 18
 <223> Degenerate oligonucleotide primer

<400> 12

arnngnccnc cnswrtncc 20

<210> 13
 <211> 12
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Fragment of TADG-15

<400> 13

Leu Phe Arg Asp Trp Ile Lys Glu Asn Thr Gly Val
 5 10

<210> 14
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> TADG-15 forward oligonucleotide primer

<400> 14

atgacagagg attcaggtac 20

<210> 15
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> TADG-15 reverse oligonucleotide primer

<400> 15

gaaggtgaag tcattgaaga

20

<210> 16

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> (-tubulin forward oligonucleotide primer

<400> 16

cgcatcaacg tgtactacaa

20

<210> 17

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> (-tubulin reverse oligonucleotide primer

<400> 17

tacgagctgg tggactgaga

20

<210> 18

<211> 3147

<212> RNA

<213> Artificial sequence

<220>

<223> Antisense of TADG-15

<400> 18

```

uuuuuuuuuu uuuuuuuuuu aaaagaaaua aauguuuuuu cccauuuaca 50
caaauacaca cacugaaguc caccucggga gcugguaaaa caauuucagu 100
cucagacccg ucuguuuucc aggguccucc gagccugggc uuccucaaga 150
gcguggccca agggcccccac agcccagauc cggcagcccc accaccuua 200
cugaggaggc uccgaagcuc cguucccgcu gcuccuuaca gacaggggag 250
gcagauauac acaaacgcgc cucggcccag cuuggggcug gcgggggagg 300
cugugucuuc aaaccuuugc ccccaguugg gucaguagaa ccaccagugu 350
ccucccuuc uaccucccag cuccacuug gaggcugagg aagcgagagg 400
uuuucuaggc agauuuggag ccugggagau ugaguucaca guguauguuc 450
ugggggcgcu ggugcaguca gcgguccagu cuccagccug caggcgugca 500
cacuggggug gacgaugggu ggccccgcag guguacacau uuggguggcc 550
ccggccccua uaccccagug uucucuuga uccagucccg aaacagaggg 600
agccuugugu acacgccugg cuuguuccuc ugagcgcagc cgucucccca 650
gcucaccaca ccggccugga agauccgcc auccgccucc acgcuggaca 700
gggguccccc ggaauacccc uggcaggagu ccacgccgcc gcugaggaag 750

```

cccacgcaca	ucaugcgcgg	cgugaucugc	ugcggcagga	gguucucgca	800
gguggucugg	uugaugacgc	ggaucucacc	cuuuugcagg	aucagcgcgc	850
cagugccucc	auacugggug	ugucucccagc	ccgugaccca	gauggccuug	900
ccggcagggg	agacauaggga	ggcguccggc	aggcagaugg	gccgcaccuau	950
ggagcuguac	ucugccgguu	ucuccagcuc	cagcagcgcg	augucauagu	1000
cgaaggugaa	gucauugaag	aagggguggg	agaugaugcg	cuugagccug	1050
cgcuccugca	ccccaggggc	gcugcgcugg	cucuggucgu	gcaagcccag	1100
gaaggccguc	cacugcgugg	ggucugagua	ccugaauccu	cugucaucga	1150
uguagcagug	ugcggcagag	accagccagu	ugggagagau	gagggagca	1200
ccgcagaugu	ggcccuggcc	cagagcaugc	aggcuuaccu	gccagggcca	1250
cucgcccuca	uccgcauccg	ugcccccac	aacacgagcc	ugucucguga	1300
augaccgcag	cccacagucg	caguccuucu	caucugagcc	gucgcuacag	1350
uccuccuucc	cgucacacuc	agggguugccc	uugcucaagc	agagcccacu	1400
gagggcagcg	uagguguguu	ugguacaagu	gacgacguuc	accuuggggc	1450
aggaggccuc	gucggacccg	uccccacagu	cguccuuccc	auugcacugc	1500
uggcuuuucg	agaggcacuu	cccduuggaa	caccugaagg	ucugggcccgg	1550
acaacugcac	cccugcucgu	cgcuuguugc	uccgcagucg	uucacacugu	1600
cgcagaccca	gaagaggggc	uugcagaacu	uguucuuugca	cgugaacugg	1650
uggccggcggu	cgcaacugca	guugagcuca	ucgcuguggu	cggugcaguc	1700
ggcccagcca	ucacagcgca	gcuccuuccg	gauacaccgc	cccugcgggc	1750
acgugaacug	ccccgggcau	gggucacugg	agucguagga	gagguaauca	1800
gcuaagaagc	cggugucggg	guaggacuga	ucugagugga	agcgaacugu	1850
gaucuuguug	cuguugcugg	ugacgacgaa	cugggaccuc	ucuccgcagu	1900
auuucucucc	auugaucucc	acguaguucc	uggggcaggu	gcccgcaggc	1950
acgccgggcu	ccagcaggua	gaagaauuug	aagcucaccu	ucacaugcug	2000
guuguugggc	accucaaugu	uccaugugca	gucaauguug	gguggguagu	2050
ggccugggua	guaggggcug	uugaaugucc	ccugggcuuu	acguaagcgg	2100
ccuccacagc	ugcucauccu	aggcagcugg	agaagguggg	ccucaaagcc	2150
gggaugccgc	cgcucagugu	ugguuauacg	ugugaugagc	aggacguucu	2200
gggaggagug	gaaggucagg	uuguaggagg	gaggguaggu	gccacacaac	2250
ugcaccaggg	cguuggggcuc	caugggggcuc	aggguuguugu	acaccgucac	2300
caggucgcug	ccgcgcucgu	cgcaggacgc	aaggucaaaag	cugcggaagg	2350
ugaggcucag	cacugagucg	gcguccccc	gcaggggcca	cuggcagcgg	2400
gcaugagcgg	gguaagggcu	gucaggggaag	ccgggcgugg	ugaagcgcau	2450
cagcuccaca	ccgcgggcu	gcaggccaaa	gcugcagcug	uuguccuggg	2500
uccucuguac	uguuuuggag	uccgugggga	aagccaccac	ugaggugacc	2550
acaaaggacu	ucagggagcg	cgcccgcggg	ggcagcauga	cuacgcgcuc	2600
cucggccaug	acgcgcucgg	ccuccuccac	caggugcugc	gggaugcuga	2650
acucagacca	guaguaggcg	augacgcugc	ccucgcugaa	ggccgucaca	2700
gccgacuccu	ugugguaggg	gcccagggaau	gggacuccgc	uguacagcag	2750
cuucagcgcg	uccuucaccu	ugcuggccag	gcuuacaaac	ucaguggagu	2800
uggaguucuc	guaggcaucc	acaaaaauuc	cauuugugau	ccucauguag	2850
ccauugaaga	ccuucuggac	acgcacgucc	cgguacugca	aaugccacac	2900
caggaagccg	auccccagca	agaccaagag	gagggccgauc	agcacggcug	2950
ccagcaccac	ccagcgcccc	gggccaugcu	uuuccaccuu	cuugacguug	3000
uugacuggca	ggaacuccac	gccuuccucc	aagccauuca	cuuucucgug	3050
ccgggaguug	uacuugaguc	ccgcgccgaa	guccuucggg	ccccuccgc	3100
ccuugcgggc	ccgaucgcuc	cccaugguac	cccagggccg	cucuuga	3147

<210> 19

<211> 9

<212> PRT

<213> Homo sapiens

<220>
 <223> Residues 68-76 of the TADG-15 protein

<400> 19

Val Leu Leu Gly Ile Gly Phe Leu Val
 5

<210> 20
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 126-134 of the TADG-15 protein

<400> 20

Leu Leu Tyr Ser Gly Val Pro Phe Leu
 5

<210> 21
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 644-652 of the TADG-15 protein

<400> 21

Ser Leu Ile Ser Pro Asn Trp Leu Val
 5

<210> 22
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 379-387 of the TADG-15 protein

<400> 22

Lys Val Ser Phe Lys Phe Phe Tyr Leu
 5

<210> 23
 <211> 9
 <212> PRT

<213> Homo sapiens

<220>

<223> Residues 386-394 of the TADG-15 protein

<400> 23

Tyr Leu Leu Glu Pro Gly Val Pro Ala
5

<210> 24

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 257-265 of the TADG-15 protein

<400> 24

Ser Leu Thr Phe Arg Ser Phe Asp Leu
5

<210> 25

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 762-770 of the TADG-15 protein

<400> 25

Ile Leu Gln Lys Gly Glu Ile Arg Val
5

<210> 26

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 841-849 of the TADG-15 protein

<400> 26

Arg Leu Pro Leu Phe Arg Asp Trp Ile
5

<210> 27
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 64-72 of the TADG-15 protein

<400> 27

Gly Leu Leu Leu Val Leu Leu Gly Ile
 5

<210> 28
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 57-65 of the TADG-15 protein

<400> 28

Val Leu Ala Ala Val Leu Ile Gly Leu
 5

<210> 29
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 67-75 of the TADG-15 protein

<400> 29

Leu Val Leu Leu Gly Ile Gly Phe Leu
 5

<210> 30
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 379-387 of the TADG-15 protein

<400> 30

Lys Val Ser Phe Lys Phe Phe Tyr Leu
 5

<210> 31
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 126-134 of the TADG-15 protein

<400> 31

Leu Leu Tyr Ser Gly Val Pro Phe Leu
 5

<210> 32
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 88-96 of the TADG-15 protein

<400> 32

Lys Val Phe Asn Gly Tyr Met Arg Ile
 5

<210> 33
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 670-678 of the TADG-15 protein

<400> 33

Thr Gln Trp Thr Ala Phe Leu Gly Leu
 5

<210> 34
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 119-127 of the TADG-15 protein

<400> 34

Lys Val Lys Asp Ala Leu Lys Leu Leu
5

<210> 35
<211> 9
<212> PRT
<213> Homo sapiens

<220>
<223> Residues 60-68 of the TADG-15 protein

<400> 35

Ala Val Leu Ile Gly Leu Leu Leu Val
5

<210> 36
<211> 9
<212> PRT
<213> Homo sapiens

<220>
<223> Residues 62-70 of the TADG-15 protein

<400> 36

Leu Ile Gly Leu Leu Leu Val Leu Leu
5

<210> 37
<211> 9
<212> PRT
<213> Homo sapiens

<220>
<223> Residues 57-65 of the TADG-15 protein

<400> 37

Val Leu Ala Ala Val Leu Ile Gly Leu
5

<210> 38
<211> 9
<212> PRT
<213> Homo sapiens

<220>
<223> Residues 61-69 of the TADG-15 protein

<400> 38

Val Leu Ile Gly Leu Leu Leu Val Leu
5

<210> 39

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 146-154 of the TADG-15 protein

<400> 39

Phe Ser Glu Gly Ser Val Ile Ala Tyr
5

<210> 40

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 658-666 of the TADG-15 protein

<400> 40

Tyr Ile Asp Asp Arg Gly Phe Arg Tyr
5

<210> 41

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 449-457 of the TADG-15 protein

<400> 41

Ser Ser Asp Pro Cys Pro Gly Gln Phe
5

<210> 42

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 401-409 of the TADG-15 protein

<400> 42

Tyr Val Glu Ile Asn Gly Glu Lys Tyr
5

<210> 43

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 387-395 of the TADG-15 protein

<400> 43

Leu Leu Glu Pro Gly Val Pro Ala Gly
5

<210> 44

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 553-561 of the TADG-15 protein

<400> 44

Gly Ser Asp Glu Ala Ser Cys Pro Lys
5

<210> 45

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 97-105 of the TADG-15 protein

<400> 45

Thr Asn Glu Asn Phe Val Asp Ala Tyr
5

<210> 46

<211> 9

<212> PRT

<213> Homo sapiens

<220>
 <223> Residues 110-118 of the TADG-15 protein

<400> 46

Ser Thr Glu Phe Val Ser Leu Ala Ser
 5

<210> 47
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 811-819 of the TADG-15 protein

<400> 47

Ser Val Glu Ala Asp Gly Arg Ile Phe
 5

<210> 48
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 666-674 of the TADG-15 protein

<400> 48

Tyr Ser Asp Pro Thr Gln Trp Thr Ala
 5

<210> 49
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 709-717 of the TADG-15 protein

<400> 49

Asp Tyr Asp Ile Ala Leu Leu Glu Leu
 5

<210> 50
 <211> 9
 <212> PRT

<213> Homo sapiens

<220>

<223> Residues 408-416 of the TADG-15 protein

<400> 50

Lys Tyr Cys Gly Glu Arg Ser Gln Phe
5

<210> 51

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 754-762 of the TADG-15 protein

<400> 51

Gln Tyr Gly Gly Thr Gly Ala Leu Ile
5

<210> 52

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 153-161 of the TADG-15 protein

<400> 52

Ala Tyr Tyr Trp Ser Glu Phe Ser Ile
5

<210> 53

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 722-730 of the TADG-15 protein

<400> 53

Glu Tyr Ser Ser Met Val Arg Pro Ile
5

<210> 54

<211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 326-334 of the TADG-15 protein

<400> 54

Gly Phe Glu Ala Thr Phe Phe Gln Leu
 5

<210> 55
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 304-312 of the TADG-15 protein

<400> 55

Thr Phe His Ser Ser Gln Asn Val Leu
 5

<210> 56
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 707-715 of the TADG-15 protein

<400> 56

Thr Phe Asp Tyr Asp Ile Ala Leu Leu
 5

<210> 57
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 21-29 of the TADG-15 protein

<400> 57

Lys Tyr Asn Ser Arg His Glu Lys Val
 5

<210> 58
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 665-673 of the TADG-15 protein

<400> 58

Arg Tyr Ser Asp Pro Thr Gln Trp Thr
 5

<210> 59
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 686-694 of the TADG-15 protein

<400> 59

Ala Pro Gly Val Gln Glu Arg Arg Leu
 5

<210> 60
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 12-20 of the TADG-15 protein

<400> 60

Gly Pro Lys Asp Phe Gly Ala Gly Leu
 5

<210> 61
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 668-676 of the TADG-15 protein

<400> 61

Asp Pro Thr Gln Trp Thr Ala Phe Leu
 5

<210> 62
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 461-469 of the TADG-15 protein
 <400> 62

Thr Gly Arg Cys Ile Arg Lys Glu Leu
 5

<210> 63
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 59-67 of the TADG-15 protein
 <400> 63

Ala Ala Val Leu Ile Gly Leu Leu Leu
 5

<210> 64
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 379-387 of the TADG-15 protein
 <400> 64

Lys Val Ser Phe Lys Phe Phe Tyr Leu
 5

<210> 65
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 119-127 of the TADG-15 protein
 <400> 65

Lys Val Lys Asp Ala Leu Lys Leu Leu

5

<210> 66

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 780-788 of the TADG-15 protein

<400> 66

Leu Pro Gln Gln Ile Thr Pro Arg Met

5

<210> 67

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 67-75 of the TADG-15 protein

<400> 67

Leu Val Leu Leu Gly Ile Gly Phe Leu

5

<210> 68

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 283-291 of the TADG-15 protein

<400> 68

Ser Pro Met Glu Pro His Ala Leu Val

5

<210> 69

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 12-20 of the TADG-15 protein

<400> 69

Gly Pro Lys Asp Phe Gly Ala Gly Leu
5

<210> 70

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 257-265 of the TADG-15 protein

<400> 70

Ser Leu Thr Phe Arg Ser Phe Asp Leu
5

<210> 71

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 180-188 of the TADG-15 protein

<400> 71

Met Leu Pro Pro Arg Ala Arg Ser Leu
5

<210> 72

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 217-225 of the TADG-15 protein

<400> 72

Gly Leu His Ala Arg Gly Val Glu Leu
5

<210> 73

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 173-181 of the TADG-15 protein

<400> 73

Met Ala Glu Glu Arg Val Val Met Leu
5

<210> 74

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 267-275 of the TADG-15 protein

<400> 74

Ser Cys Asp Glu Arg Gly Ser Asp Leu
5

<210> 75

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 567-575 of the TADG-15 protein

<400> 75

Cys Thr Lys His Thr Tyr Arg Cys Leu
5

<210> 76

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 724-732 of the TADG-15 protein

<400> 76

Ser Ser Met Val Arg Pro Ile Cys Leu
5

<210> 77

<211> 9

<212> PRT

<213> Homo sapiens

<220>
 <223> Residues 409-417 of the TADG-15 protein
 <400> 77

Tyr Cys Gly Glu Arg Ser Gln Phe Val
 5

<210> 78
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 495-503 of the TADG-15 protein
 <400> 78

Thr Cys Lys Asn Lys Phe Cys Lys Pro
 5

<210> 79
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 427-435 of the TADG-15 protein
 <400> 79

Val Arg Phe His Ser Asp Gln Ser Tyr
 5

<210> 80
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 695-703 of the TADG-15 protein
 <400> 80

Lys Arg Ile Ile Ser His Pro Phe Phe
 5

<210> 81
 <211> 9

<212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 664-672 of the TADG-15 protein

<400> 81

Phe Arg Tyr Ser Asp Pro Thr Gln Trp
 5

<210> 82
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 220-228 of the TADG-15 protein

<400> 82

Ala Arg Gly Val Glu Leu Met Arg Phe
 5

<210> 83
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 492-500 of the TADG-15 protein

<400> 83

His Gln Phe Thr Cys Lys Asn Lys Phe
 5

<210> 84
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 53-61 of the TADG-15 protein

<400> 84

Gly Arg Trp Val Val Leu Ala Ala Val
 5

<210> 85
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 248-256 of the TADG-15 protein

<400> 85
 Leu Arg Gly Asp Ala Asp Ser Val Leu
 5

<210> 86
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 572-580 of the TADG-15 protein

<400> 86
 Tyr Arg Cys Leu Asn Gly Leu Cys Leu
 5

<210> 87
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 692-700 of the TADG-15 protein

<400> 87
 Arg Arg Leu Lys Arg Ile Ile Ser His
 5

<210> 88
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 24-32 of the TADG-15 protein

<400> 88
 Ser Arg His Glu Lys Val Asn Gly Leu
 5

<210> 89
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 147-155 of the TADG-15 protein

<400> 89

Ser Glu Gly Ser Val Ile Ala Tyr Tyr
 5

<210> 90
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 715-723 of the TADG-15 protein

<400> 90

Leu Glu Leu Glu Lys Pro Ala Glu Tyr
 5

<210> 91
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 105-113 of the TADG-15 protein

<400> 91

Tyr Glu Asn Ser Asn Ser Thr Glu Phe
 5

<210> 92
 <211> 9
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Residues 14-22 of the TADG-15 protein ,

<400> 92

Lys Asp Phe Gly Ala Gly Leu Lys Tyr

5

<210> 93

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 129-137 of the TADG-15 protein

<400> 93

Ser Gly Val Pro Phe Leu Gly Pro Tyr

5

<210> 94

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 436-444 of the TADG-15 protein

<400> 94

Thr Asp Thr Gly Phe Leu Ala Glu Tyr

5

<210> 95

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 766-774 of the TADG-15 protein

<400> 95

Gly Glu Ile Arg Val Ile Asn Gln Thr

5

<210> 96

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 402-410 of the TADG-15 protein

<400> 96

Val Glu Ile Asn Gly Glu Lys Tyr Cys
5

<210> 97

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 482-490 of the TADG-15 protein

<400> 97

Asp Glu Leu Asn Cys Ser Cys Asp Ala
5

<210> 98

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Residues 82-90 of the TADG-15 protein

<400> 98

Arg Asp Val Arg Val Gln Lys Val Phe
5

CLAIMS:

1. A method of detecting TADG-15 protein in a sample, comprising the steps of:
 - (a) contacting a sample with an antibody, wherein said antibody is specific for a TADG-15 fragment consisting of SEQ ID NO: 19, 20, 21, 29, 39, 49, 50, 59, 79, 80, 81, 82, 83, 84, 89 or 90; and
 - (b) detecting binding of said antibody to TADG-15 protein in said sample.
2. The method of claim 1, wherein said sample is a biological sample.
3. The method of claim 2, wherein said biological sample is from an individual.
4. The method of claim 3, wherein said individual is suspected of having cancer.
5. A kit for detecting TADG-15 protein, comprising:
 - an antibody specific for a TADG-15 fragment consisting of SEQ ID NO: 19, 20, 21, 29, 39, 49, 50, 59, 79, 80, 81, 82, 83, 84, 89 or 90; and
 - means to detect said antibody.
6. An immunogenic composition, comprising:
 - an immunogenic fragment of a TADG-15 protein, wherein said fragment consists of SEQ ID NO: 19, 20, 21, 29, 39, 49, 50, 59, 79, 80, 81, 82, 83, 84, 89 or 90; and
 - an appropriate adjuvant.

RIVGGRDTSL	GRWPWQVSL.	RYDG.A	HLCGGSLLSG	DWVLTAACHF	PE....RNRV	LSRWRVFAGA	VAQASPHGLQ
RVVGGTDADE	GEWPWQVSL.	HALGQG	HICGASLISP	NWLVSAAHCY	IDDRGFRYS	PTQWTAFLGL	HDQSQRSAPG
KIIDGAPCAR	GSHPWQVAL.	LSGNQL	H.CGGVLVNE	RWVLTAACH.	K	MNEYTVHLGS	DTLG..DR.R
KIVGGYNCEE	NSVPYQVSL.	NSGYHF	..CGGSLINE	QWVVSAGHC.	Y	KSRIQVRLGE	HNIEVLEG.N
RIVNGEDAVP	GSWPWQVSL.	QDKTGF	HFCGGSLISE	DWVVTAACH.	GV	RTSDVVVAGE	FDQGSDEE.N
RIVGKVCVK	GECPWQVLL.	LVNG.A	QLCGGTLINT	IWVVSAAHCF	DKIKNWRNLI	AVLGE	HDLSEHDGDE
RIKGGLFADI	ASHPWQAAIF	AKHRRSPGER	FLCGGILISS	CWILSAAHCF	QERFPPHHL.	TVILGR	.TYRVVPGEE
★							
LGVAQVVYHG	GYPFRDPNS	EENSNDIALV	HLSS.PLPLT	EYIQPVCLPA	...AGQALVD	GKICTVTGWG	NTQYYGQQ.A
VQERRLKRII	SHPFNDFTF	D...YDIALL	ELEK.PAEYS	SMVRPICLPD	...ASHVFPA	GKAIWVTGWG	HTQYGGTG.A
AQRIKASKSF	RHPGYSTQT.	..HVNDMLV	KLNS.QARLS	SMVKKVRLLS	...RCE..PP	GTCTCTVSGWG	TTTSPDVTFF
EQFINAAKII	RHPQYDRKT.	..LNNDIMLI	KLSS.RAVIN	ARVSTISLPT	...APP..AT	GTKCLISGWG	NTASSGADYP
IQVLKIAKVF	KNPKFSILT.	..VNNDITLL	KLAT.PARFS	QTVSAVCLPS	...ADDDFPA	GTLCATTTGWG	KTKYNANKTP
QSRRVAAQVII	P...STYVP	GTNHDIALL	RLHQ.PVVL	DHVVPCLLPE	RTFSERTLAF	VRFSLVSGWG	QLLDRGATAL
EQKFEVEKYI	VHKEFDDDTY	D...NDIALL	QLKSDSSRCA	QESSVVRTVC	LPPADLQLPD	WTECELSGYG	KHEALSPFYS
★							
GVLQEARVPI	ISNDVCNGAD	FYGN..QIKP	KMFCAGYPEG	G.....IDA	CQGDSCGGPFV	CEDSISRTPR	WRLCGIVSWG
LILQKGEIRV	INQTTCE..N	LLPQ..QITP	RMCMCVGFLSG	G.....VDS	CQGDSCGGPL.	..SSVEADGR	IFQAGVVSWG
SDLMCVDVKL	ISPQDCTKV.	.YKD..LLEN	SMLCAGIPDS	K.....KNA	CNGDSGGPLV	C....R....	GTLQGLVSWG
DELQCLDAPV	LSQAKCEAS.	.YPG.;KIT	NMFCVGFLEG	G.....KDS	CQGDSCGGPVV	C....N....	GQLQGVVSWG
DKLQQAALPL	LSNAECKKS.	.WGR..RITD	VMICAG..AS	G.....VSS	CMGDSGGPLV	C....QKDG	WTLVGIVSWG
ELMVLNVPR	MTQDCLQQSR	KVGDSPNITE	YMFAGYS	SDG	CKGDSCGGP..	..HATHYRGT	WYLTGIVSWG
ERLKEAHVRL	YPSSRCTSQH	LLNRT..VTD	NMLCAGDTRS	GGPQANLHDA	CQGDSCGGPLV	CLN....DGR	MTLVGIISWG
★							
T.GCALAQKP	GVYTKVSDER	EWIFQAIKTH	SEASGMVTQL	~~	(SEQ. ID NO: 3)	Heps	
D.GCAQRNKP	GVYTRLPLFR	DWIKENTGV~	~~~~~	~~	(SEQ. ID NO: 14)	Tadg 15	
TFPCGQPNDP	GVYTQVCKFT	KWINDTMKKH	R~~~~	~~	(SEQ. ID NO: 4)	Scce	
D.GCAQKNKP	GVYTKVYNYV	KWIKNTIAAN	S~~~~	~~	(SEQ. ID NO: 5)	Try	
SDTCS.TSSP	GVYARVTKLI	PWVQKILAAN	~~~~~	~~	(SEQ. ID NO: 6)	Chymb	
Q.GCATVGHF	GVYTRVSQYI	EWLQKLMRSE	PRPGVLLRAP	FP	(SEQ. ID NO: 7)	Fac 7	
.LGGQKQDVP	GVYTKVTNYL	DWIRDNMRP~	~~~~~	~~	(SEQ. ID NO: 8)	Tpa	

FIG. 1

1 TCAAGAGCGCCTCGGGGTACCATGGGAGCGATCGGGCCGCAAGGCGGAGGGGCCGAAGACTTCGGCGCGGACTC
 M G S D R A R K G G G P K D F G A G L
 83 AAGTAACTCCCGCACGAGAAAGTGAATGGCTTGGAGGAAGCGTGGAGTTCCTGCCAGTCAACAACGTCAAGAAGGTG
 K Y N S R H E K V N G L E E G V E F L P V N N V K K V
 164 GAAAAGCATGGCCCGGGCGCTGGTGGTGGTGGCAGCCGTGCTGATCGGCCCTCCTCTTGGTCTTGGTGGGATCGGCTTC
 E K H G P G R [W V V L A A V L I G L L V L L G I G F
 245 CTGGTGGCATTTGCAGTACCGGACGTGCGTGTCAGAAAGTCTTCAATGGCTACATGAGGATCACAATGAGAAATTT
 L V W] H L Q Y R D V R V Q K V F N G Y M R I T N E N F
 326 GTGGATGCCCTACGAGAACTCCAACCTCAGTGTGTAAGCCTGGCCAGCAAGTGAAGGACGCGCTGAAGCTGCTGTAC
 V D A Y E N S N S T E F V S L A S K V K D A L K L L Y
 407 AGCGAGTCCCATTCCTGGGCCCTACCACAAGAGTCGGCTGTGACGGCCTTCAGCGAGGCGAGCTCATCGCCTACTAC
 S G V P F L G P Y H K E S A V T A F S E G S V I A Y Y
 488 TGGTCTGAGTTCAGCATCCCGCAGCACCTGGTGAGGAGCGCGCTCATGCGGAGCGGCTAGTCAATGCTGCCCC
 W S E F S I P Q H L V E E A E R V M A E E R V V M L P
 569 CCGGGGCGGCTCCCTGAAGTCCTTTGTGTCACCTCAGTGGTGGCTTTCCCCACGACTCCAAAACAGTACAGAGACC
 P R A R S L K S F V V T S V V A F P T D S K T V Q R T
 650 CAGGACAAAGCTGCAGCTTTGGCCTGACGCCCCGGTGTGGAGCTGATGCGCTTCACCACGCCCCGGCTTCCCTGACAGC
 Q D N S C S F G L H A R G V E L M R F T T P G F P D S
 731 CCCTACCCGCTCATGCCCGCTGCCAGTGGGCCCTGCGGGGACGCCGACTCAGTGTGAGCTCACCTTCCGCAGCTTT
 P Y P A H A R C Q W A L R G D A D S V L S L T F R S F
 812 GACCTTGGTCCGACGAGCGCGGACGACCTGGTGACGGTGTACAACACCTGAGCCCCCATGGAGCCCCACGCCCTG
 D L A S C D E R G S D L V T V Y N T L S P M E P H A L
 893 GTGCAGTTGTGGCACCTACCTCCCTCCTTACAACTGACCTTCCACTCCTCCAGAACGTCCTGCTCATCAGCTGATA
 V Q L C G T Y P P S Y N L T F H S S Q N V L L I T L I

FIG. 2-1

974 ACCAACA CTGAGCGGCGCATCCCGGCTTTGAGGCCACCTTCTCCAGCTGCCCTAGGATGAGCAGCTGTGGAGGCCGCTTA
 T N T E R R H P G F E A T F F Q L P R M S S C G G R L
 1055 CGTAAAGCCAGGGGACATTCAACAGCCCCCTACTACCCAGGCCACTACCCACCAACATTGACTGCACATGGAACATTGAG
 R K A Q G T F N S P Y Y P G H Y P P N I D C T W N I E
 1136 GTGCCCAACAACAGCATGTGAAGGTGAGCTTCAAATTTCTACCTGTGGAGCCCCGGCTGCCCTGGGGCACCTGCCCCC
 V P N N Q H V K V S F K F F Y L L E P G V P A G T C P
 1217 AAGGACTACGTGGAGATCAATGGGAGAAATACTGCGGAGAGAGTCCCAGTTCGTCGTCAACAGCAACAGCAAGATC
 K D Y V E I N G E K Y C G E R S Q F V V T S N S N K I
 1298 ACAGTTTCGCTTCCACTCAGATCAGTCCCTACACCCGACACCCGGCTTCTTAGCTGAATACCTCTCTACGACTCCAGTGACCCA
 T V R F H S D Q S Y T D T G F L A E Y L S Y D S S D P
 1379 TGCCCGGGCAGTTCACGTGCCCGCACGGGGGTGTATCCGGAAGGAGCTGCGCTGTGATGGCTGGGCCGACTGCACCGAC
 C P G Q F T C R T G R C I R K E L R C D G W A D C T D
 1460 CACAGCGATGAGCTCAACTGCAGTTGCGACCGCGGCCAGTTCACGTGCAAGAACAAGTTCTGCAAGCCCCCTCTCTGG
 H S D E L N C S C D A G H Q F T C K N K F C K P L F W
 1541 GTCTGCGACAGTGTGAACGACTGCGGAGACAACAGCGACGAGGGGTGCAGTTGTCCGGCCCCAGACCTTCAGGTGTTCC
 V C D S V N D C G D N S D E Q G C S C P A Q T F R C S
 1622 AATGGGAAGTGCCCTCTCGAAAAGCCAGGAGTGCAATGGGAAGGACGACTGTGGGACGGTCCGACGAGGCCCTCCTGCCCCC
 N G K C L S K S Q Q C N G K D D C G D G S D E A S C P
 1703 AAGGTGAACGTCGTCACTTGTACCAACAACACACCTACCGCTGCCTCAATGGGCTCTGCTTGAGCAAGGCAACCTGAGTGT
 K V N V V T C T K H T Y R C L N G L C L S K G N P E C
 1784 GACGGGAAGGAGGACTGTAGCGACGGCTCAGATGAGAAGGACTGCGACTGTGGGCTGCGGTCAATTCACGAGACAGGCTCGT
 D G K E D C S D G S D E K D C D C G L R S F T R Q A R
 1865 GTTGTGGGGCACGGATGCGGATGAGGGCGAGTGGCCCTGGCAGGTAAGCCTGCATGCTCTGGGCCAGGCCACATCTGC
 V V G G T D A D E G E W P Q V S L H A L G Q G H I C
 1946 GGTGCTTCCCTCATCTCTCCAACTGGCTGTCTCTGCCGCACACTGTACATCGATGACAGAGGATTCAGGTACTCAGAC
 G A S L I S P N W L V S A A A **(H)** C Y I D D R G F R Y S D

FIG. 2-2

2027 CCCACGAGTGGACGGCCTTCCTGGGCTTGACGACCAGAGCCAGCGCCCTGGGGTGCAGGAGCGCAGGCTCAAG
P T Q W T A F L G L H D Q S Q R S A P G V Q E R R L K
2108 CGCATCATCTCCACCCCTTCTTCAATGACTTCACCTTCGACTATGACATCGCGTGTGGAGCTGGAGAAACCGGCAGAG
R I I S H P F F N D F T F D Y (D) I A L L E L E K P A E
2189 TACAGCTCCATGGTGGGCCCATCTGCCTGCGGACGCCCTCCCATGTCTTCCCTGCCGCAAGGCCATCTGGGTCACGGGC
Y S S M V R P I C L P D A S H V F P A G K A I W V T G
2270 TGGGACACACCCAGTATGGAGGCACTGGCGGCTGATCCTGCAAAAGGGTGAGATCCGCGTCATCAACCAGACCCTGC
W G H T Q Y G G T G A L I L Q K G E I R V I N Q T T C
2351 GAGAACCTCCTGCCGAGCAGATCACGCCGCGCATGATGTGCGTGGGCTTCTCAGCGCGCGGTGGACTCCTGCCAGGGT
E N L L P Q Q I T P R M C V G F L S G G V D S C Q G
2432 GATTCGGGGACCCCTGTCCAGCGTGGAGGCGGATCTTCCAGGCCGCTGTGGTGAGCTGGGAGACGGCTGC
D (S) G G P L S S V E A D G R I F Q A G V V S W G D G C
2513 GCTCAGAGGAACAAGCCAGCGGTACACAAGCTCCCTCTGTTCGGGACTGGATCAAGAGAACAACACTGGGGTATAGGGG
A Q R N K P G V Y T R L P L F R D W I K E N T G V
(SEQ ID NO: 2)
2594 CCGGGGCCACCCAAATGTGTACACCTGCGGGGCCACCCATCGTCCACCCAGTGTGCACGCCCTGCAGGCTGGAGACTGGAC
2675 CGCTGACTGCACCGCGCCCCAGAACATACACTGTGAACCTCCAGGGCTCCAAATCTGCCTAGAAAACCTCTCGC
2756 TTCCCTCAGCCTCCAAGTGGAGCTGGAGGTAGAAAGGGAGGACACTGGTGGTCTACTGACCCAACTGGGGCAAAGGTT
2837 TGAAGACACAGCCTCCCCCGCCAGCCCCAAGCTGGCCGAGCGCGTTTGTGTATATCTGCCTCCCCCTGTCTGTAAAGGAGC
2918 AGCGGGAACGGAGCTTCGGAGCCTCCTCAGTGAAGTGGTGGGCTGCCGGATCTGGGCTGTGGGCCCTTGGGCCACGCT
2999 CTTGAGGAAGCCAGGCTCGGAGGACCCCTGGAAACAGACGGGTCTGAGACTGAAATTGTTTACCAGCTCCCAGGTTGGA
3080 CTTCAGTGTGTATTGTGTAAATGGGTAAACAATTATTCTTTTAAATAAAAAA (SEQ ID NO: 1)

[] : KOZAK'S CONSENSUS SEQUENCE

[] : TRANSMEMBRANE DOMAIN

O : CONSERVED AMINO ACIDS OF CATALYTIC TRIAD H,D,S

FIG. 2-3

1 MGSDRARKGG GGPKDFGAGL KYNSRHEKVN GLEEGVEFLP VNNVKKVEKH 1
 51 GPGRWVVLAA VLIIGLLVLL GIGFLVWHLQ YRDVRVQKVF NGYMRITNEN 2
 101 FVDAYENSNS TEFVSLASKV KDALKLLYSV VPFLGPYHKE SAVTAFSEGS
 151 VIAYYWSEFS IPQHLVEEAE RVMAEERVVM LPPRARSLSKS FVVTSVVAFP
 201 TDSKTVQRTQ DNS^{*}CSFGLHA RGVELMRFTT PGFPDSPYPA HARCQWALRG
 251 DADSVLSLTF RSFDLAS^{*}CDE RGSDLVTVYN TLSPMEPHAL VQL^{*}CGTYPFS 3
 301 YNLTFHSSQN VLLITLITNT ERRHPGFEEAT FFQLPRMSS^{*}C GGRLRKAQGT
 351 FNSPYYPGHY PPNID^{*}CTWNI EVPNNQHVKV SFKFFYLLEP GVPAGTC^{*}PKD
 401 YVEINGEKYC^{*} GERSQFVVT NSNKITVRFH SDQSYTDTGF LAEYLSYDSS
 451 DPCPGQFTCR TGR CIRKELR CDGWADCTDH SDE LNCSCDA GHQFTCKNKF
 501 CKPLFWVCD S VND CGDN SDE QGCSCPAQTF RCSNGKCLSK SQQCNGKDDC 4
 551 GDG SDE ASCP KVNVTCTKH TYRCLNGLCL SKGNPECDGK EDCSDG SDE K
 601 DCDCGLRSFT RQARVVGTD ADEGEWPWQV SLHALGQGH I CGASLISP NW
 651 LVSAAH CYID DRGFRYSDPT QWTAFLGLHD QSQRSAPGVQ ERRLKRIISH
 701 PFFNDFTFDY DIALLELEKP AEYSSMRPI CLPDASHVFP AGKAIWVTGW 5
 751 GHTQYGGTGA LILQKGEIRV INQTTENLL PQQITPRMMC VGFLSGGVDS
 801 CQGD SGGPLS SVEADGRIFQ AGVVSWDGC AQRNKPGVYT RLPLFRDWIK
 851 ENTGV (SEQ. ID NO: 2)

^{*} : Conserved cysteine residue

NXT : Possible N-linked glycosylation site

SDE : Conserved SDE motif ..

▼ : Potential cleavage site

○ : Conserved amino acids of catalytic triad H, D, S

1. Cytoplasmic domain

2. Transmembrane domain

3. CUB repeat

4. Ligand-binding repeat (class A motif)
of LDL receptor like domain

5. Serine protease

FIG. 3




FIG. 4




FIG. 5




FIG. 6A




FIG. 6B




FIG. 7




FIG. 8




FIG. 9



FIG. 10A



FIG. 10B



FIG. 10C




FIG. 10D



FIG. 10E

hTADG15	MGSDRARKGG	GGPKDFGAGL	KYNSRHEKVN	GLEEGVEFLP	VNNVKKVEKH	50
mEpithin	---N-G--A-	--SQ-----	--D--L-NM-	-F-----	A--A-----R	
hTADG15	GPGRWVVLAA	VLIGLLLVLL	GIGFLVWHLQ	YRDVRVQKVF	NGYMRITNEN	100
mEpithin	--R-----V-	--FSF--LS-	MA-L-----FH	--N-----	--HL-----I	
hTADG15	FVDAYENSNS	TEFVSLASKV	KDALKLLYSG	VPFLGPYHKE	SAVTAASEGS	150
mEpithin	-L-----T-	---I-----Q-	-E-----NE	--V-----K	-----	
hTADG15	VIAYYWSEFS	IPQHLVEEAE	RVMAEERVVM	LPPRARSLS	FVVTSVVAEP	200
mEpithin	-----	--P--A--VD	-A--V-----T	-----A---	--L-----	
hTADG15	TDSKTVQRTQ	DNSCSEGLHA	RGVELMRFTT	PGFPDSPYPA	HARCQWALRG	250
mEpithin	I-PRML----	-----A---	H-AAVT----	---N-----	-----V---	
hTADG15	DADSVLSLTF	RSFDLASCDE	RGSDLVTVYN	TLSPMEPHAL	VQLCGTYPPS	300
mEpithin	-----	----V-P---	H-----D	S-----V	-R-----FS--	
hTADG15	YNLTFHSSQN	VLLITLITNT	ERRHPGFEAT	FFQLPRMSSC	GGRLRKAQGT	350
mEpithin	-----L----	-F-V-----	G---L-----	-----K----	--V-SDT----	
hTADG15	FNSPYYPGHI	PPNIDCTWNI	EVPNNQHVKV	SEKFFYLLEP	GVPAGTCPKD	400
mEpithin	-S-----	-----N-----	K-----RN---	R--L---VD-	N--V-S-T--	
hTADG15	YVEINGEKYC	GERSQFVVT	NSNKITVREH	SDQSYTDGTF	LAEYLSYDSS	450
mEpithin	-----GS	-----S-	--S-----H--	--H-----	-----N	

FIG. 11-1

hTADG15	DPCPGQFTCR	TGRCIRKELR	CDGWADCTDH	SDELNCSCDA	GHQFTCKNKF	500
mEpithin	-----M-M-K	-----	-----P-Y	---RY-R-N-	T-----Q-	
hTADG15	CKPLEFWCDS	VNDCGDNSE	QGCSCPAQTF	RCSNGKCLSK	SQQCNGKDDC	550
mEpithin	-----	-----G---	E-----GS-	K-----PQ	--K-----N-	
hTADG15	GDGSDEASCP	KVNVTCTKH	TYRCLNGLCL	SKGNPECDGK	EDCSDGSDEK	600
mEpithin	-----D	S-----S---Y	-----Q-----	-----	T-----	
hTADG15	DCDCGLRSET	RQARVVGTD	ADEGEWPQV	SLHALGQGHI	CGASLISPNW	650
mEpithin	N-----	K-----N	-----	-----L	-----D-	
hTADG15	LVSAAHCYID	DRGFRYSDPT	QWTAFLGLHD	QSQRSAPGVQ	ERRLKRIISH	700
mEpithin	-----FQ-	-KN-K---Y-	M-----L-	--K---S---	-LK-----T-	
hTADG15	PFENDETFDY	DIALLELEKP	AEYSSMVRPI	CLPDASHVEP	AGKAIWVTGW	750
mEpithin	-S-----	-----S	V---TV---	-----T---	-----	
hTADG15	GHTQYGGTGA	LILQKGEIRV	INQTCENLL	PQQITPRMMC	VGFLSGGVDS	800
mEpithin	---KE-----	-----	-----D-M	-----	-----	
hTADG15	CQGDGGPLS	SVEADGRIEQ	AGVSWGDGC	AQRNKPGVYT	RLPLFRDWIK	850
mEpithin	-----	-A-K---M--	-----E--	-----	---CSSGLDQ	
hTADG15	ENTGV*					900
mEpithin	RAHWGIAAWT	DSRPQTPTGM	PDMHTWIQER	NTDDIYAVAS	PFQHNPDCEL	
hTADG15		SEQ ID NO: 2				
mEpithin	HP	SEQ ID NO: 10				902

FIG. 11-2

499 CCGCGGTGGAGCTGATGCGCTTCACCACG.CCGGCTTCCCTGACAGCCCTACCCGCTCATGCCCGCTGCCAGTGGGC...TGCGGGGACG.CGAC 592

16/18

FIG. 12-2

1575 GCGACGAGCAGGGTGCAGTTGTCCGG.CCCAGACCTTCAGGTGTTCCAATGGGAAGTGCCCTCTCGAAAGCCAGCAGTGCAATGGGAAGGACGACTGTG 1673
||||| 1674 GGGACGGGTCCGACGAGGCCTCCTGCCCCAAGGTGAACGTCGTCACCTTGTACCAAAACACACCTACC'GCTGCCCTCAATGGGGCTCTGCTTGAGCAAGGCAA 1773
||||| 1478 GGGACGGGTCCGACGAGGCCTCCTGCCCCAAGGTGAACGTCGTCACCTTGTACCAAAACACACCTACC'GCTGCCCTCAATGGGGCTCTGCTTGAGCAAGGCAA 1577
||||| 1774 CCCTGAGTGTGACGGGAAGGAGGACTGTAGCGACGGCTCAGATGAGAAGGACTGCGACTGTGGGCTGCGGTCAATCAGAGACAGGCTCGTGTGTTGGG 1873
||||| 1578 CCCTGAGTGTGACGGGAAGGAGGACTGTAGCGACGGCTCAGATGAGAAGGACTGCGACTGTGGGCTGCGGTCAATCAGAGACAGGCTCGTGTGTTGGG 1677
||||| 1874 GGCACGGATGCGGATGAGGGCGAGTGGCCCTGGCAGGTAAGCCTGCATGCTCTGGGCCAGGGCCACATCTGCGGTGCTTCCCTCATCTCTCCCAACTGGC 1973
||||| 1678 GGCACGGATGCGGATGAGGGCGAGTGGCCCTGGCAGGTAAGCCTGCATGCTCTGGGCCAGGGCCACATCTGCGGTGCTTCCCTCATCTCTCCCAACTGGC 1777
||||| 1974 TGGTCTCTGCCCGCACACTGCTACATCGATGACAGAGGATTGAGGACTCAGAGCCCTTCCCTGGGCTTGCACGACGAGCCAGCG 2073
||||| 1778 TGGTCTCTGCCCGCACACTGCTACATCGATGACAGAGGATTGAGGACTCAGAGCCCTTCCCTGGGCTTGCACGACGAGCCAGCG 1875
|| | 2074 CAGCGCCCTGGGGTGACGAGCGCAGGCTCAAGCGCATCATCTCCACCCCTTCTTCAATGACTTCACCTTCGACTATGACATCGCGCTGCTGGAGCTG 2173
1876 CA..GGCCCTGGGGTGACGAGCGCAGGCTCAAGCGCATCATCTCCACCCCTTCTTCAATGACTTCACCTTCGACTATGACATCGCGCTGCTGGAGCTG 1973
2174 GAGAAACCGGCAGAGTACAGCTCCATGGTGCGGGCCCATCTGCCCTGCCGGACGCCTCCCATGTCTTCCCTGCCGGCAAGGCCATCTGGGTACCGGGCTGGG 2273
1974 GAGAAACCGGCAGAGTACAGCTCCATGGTGCGGCCATCTGCCCTGCCGGACGCCTGCCATGTCTTCCCTGCCGGCAAGGCCATCTGGGTACCGGGCTGGG 2073
2274 GACACACCCAGTATGAGGCACCTGGCGCGCTGATCCTGCAAAAGGGTGAGATCCGCGTCAATCAACAGACCACTGCGAGAACCTCCTGCCGACAGAT 2373
2074 GACACACCCAGTATGAGGCACCTGGCGCGCTGATCCTGCAAAAGGGTGAGATCCGCGTCAATCAACAGACCACTGCGAGAACCTCCTGCCGACAGAT 2173

FIG. 12-3

2374 CACGCCGCGCATGATGTCGTGGGCTTCCTCAGCGGCGCGTGGACTCCTGCCAGGGTGATTCCGGGGACCCCTGTCCAGCGTGAGCGGATGGCGG 2473
|||||
2174 CACGCCGCGCATGATGTCGTGGGCTTCCTCAGCGGCGCGTGGACTCCTGCCAGGGTGATTCCGGGGACCCCTGTCCAGCGTGAGCGGATGGCGG 2273
|||||
2474 ATCTTCCAGGCCGGTGTGGTGAGCTGGGGAGACGGCTCAGAGGAACAAGCCAGGCTCCCTCTGTTCGGGACTGGATCAAAG 2573
|||||
2274 ATCTTCCAGGCCGGTGTGGTGAGCTGGGGAGAC.GCTGCGCTCAGAGGAACAAGCCAGGCTCCCTCTGTTCGGGAATGGATCAAAG 2372
|||||
2574 AGAACACTGGGGTATAGGGGCCGGGCCACCCAAATGTGTACACCTGCGGGGCCACCCATCGTCCACCCAGTGTGCACGCCCTGCAGGCTGGAGACT... 2670
|||||
2373 AGAACACTGGGGTATAGGGGCCGGGCCACCCAAATGTGTACACCTGCGGGGCCACCCATCGTCCACCCAGTGTGCACGCCCTGCAGGCTGGAGACTCGC 2472
|||||
2671 GGACCGCTGACTGCACCCAGCGCCCCAGAACATACACTGTGAACTCAATCTCAGGGCTCCAAATCGCCTAGAAAACCTCTCGCTTCCTCAGCCTCCAA 2770
|||||
2473 GCACCGTGACCTGCACCAGCG.CCCCAGAACATACACTGTGAACTC.ATCTCCAGG..CTCAAATCTG.CTAGAAAACCTCTCGCTTCCTCAGCCTCCAA 2567
|||||
2771 AGTGAGCTGGGA.GGTAGAAAGGGAGG.ACACCTGGTGGTTCTACTGACCCAACTGGGGGCAAAGGTTTGAAGACACAGCCTCCCCGCCAGCCCCAAGC 2868
|||||
2568 AGTGGAGCTGGGAGGTTAGAAAGGGAGGAACACTGGTGGTTCTACTGACCCAACTGGGG..CAAGGTTGAAG.CACAG...CTCCGGCAGCCC..AAG 2658
|||||
2869 TGGGCCGAGCGCGTTTGTGTATATCTGCCCTCCCCTGTCTGTAAAGGAGCAGCGGGAACGGAGCTTCGGAGCCTCCTCAGTGAAGTGTTGGGTGCCCG 2968
|||||
2659 TGGGCGAGGACGCGTTTGTGCATA.CTGCC.CTGCTCTATACACGGAAAGACCTGGA.....TCTCTAGTGA.....GTGTGACTGCCCG 2735
|||||
2969 ATCTGGGCTGTGGGGCCCTTGGGGCCACGCTCTTGAGGAAGCCCAGGCTCGGAGACCCCTGGAAAACAGACGGGTCTGAGACTGAAATGTTTACCAGCT 3068
|||||
2736 ATCTGG...CTGTGTCCTTGGCCACGCTTCTTGAGGAAGCCCAGGCTCGGAGACCCCTGGAAAACAGACGGGTCTGAGACTGAAAATGGTTTACCAGCT 2832
|||||
3069 CCCAGGTGGACTTCAGTGTGTGTAATTGTGTAAATGGGTAAACAATTATTCTTTTAAAAAATAAAAAA 3147 (SEQ. ID NO: 1)
|||||
2833 CCCAGG..TGACTTCAGTGTGTGTA.TTGGTAAATGAGTAAACAATTTTATTCTTTTAAAAAATAAAAAA..... 2900 (SEQ. ID NO: 9)

FIG. 12-4